Competence Atlas Hessen-Biotech€¦ · Competence Atlas Hessen-Biotech The Spectrum of Biotechnology Companies in Hessen 2015 Volume 17 of the publication series of Hessen-Biotech

Ministry of Economics, Energy, Transport and Regional Development, State of Hessen

www.hessen-biotech.de

Competence Atlas Hessen-BiotechThe Spectrum of Biotechnology Companies in Hessen 2015

Hessen Biotech

Hessen – there’s no way around us.

Ladies and Gentlemen,

Biotechnology is now an indispensable, integral component of numerous industrial

processes and even of our everyday lives. In the field of medicine, it contributes

to earlier detection and better treatment of illnesses by way of new diagnostic

procedures and drugs. In commerce, it is the key to the switchover from fossil to

renewable raw materials. Synthetic materials, base chemicals, energy – we can

produce all these with the aid of biotechnology.

Hessen is optimally positioned in this promising domain. Our universities, research

institutions and start-ups constitute the ideal breeding ground for innovation. In the

laboratories of the Hessian chemical and pharmaceutical industry, ideas quickly

grow so as to be ready for application. Production is not a distant prospect: Close

to one third of Germany’s biotechnological production capacity is sited in Hessen.

The Hessen-Biotech Competence Atlas 2015 provides you with an overview of the

Hessian biotechnology industry. It features 169 companies and institutions. Innova-

tion-driven industries such as biotechnology derive sustenance from cooperation

between various partners. With the Hessen-Biotech Competence Atlas, we aim to

facilitate such cooperation, transcending both subject-specific and geographical

boundaries.

Tarek Al WazirMinister for Economics, Energy, Transportand Regional Development, State of Hessen

1

2

Foto Cover: Alexander Raths | Fotolia.com

BillionPhotos.com | Fotolia.com

endostock | Fotolia.com

ImprintCompetence Atlas Hessen-BiotechThe Spectrum of Biotechnology Companies in Hessen 2015

Volume 17 of the publication series of Hessen-Biotechof the Ministry of Economics, Energy, Transport andRegional Development, State of Hessen.

Publisher:

Hessen Trade & Invest GmbH

Konradinerallee 9

65189 Wiesbaden, Germany

Phone +49 611 95017-85

Fax +49 611 95017-8620

www.htai.de


The publisher does not take any responsibilty for correctness,

preciseness and completeness of the given information.

Opinions and views expressed in the publication do not

necessarily reflect those of the publisher.

© Ministry of Economics, Energy, Transport

and Regional Development, State of Hessen.

Jens Krüger

Kaiser-Friedrich-Ring 75

65185 Wiesbaden, Germany

www.wirtschaft.hessen.de

Reproduction and reprint – even in parts – subject to prior

written approval.

Project Management:

Technologielinie Hessen-Biotech

Dr. Detlef Terzenbach (Director), Lena Haupt

Hessen Trade & Invest GmbH, Wiesbaden

Editors:

Lena Haupt, Hessen Trade & Invest GmbH

Mai Lan Phan, BCNP Consultants GmbH, Frankfurt am Main

Layout:

Theißen Design, Lohfelden

Print:

A&M Service GmbH, Elz

Dezember 2015

Contents

Editorial ....................................................................................................................................... 4

Company Profiles ................................................................................................................. 13

Classified Register ............................................................................................................... 77

R & D Centers ......................................................................................................................... 85

Publication series of Hessen-Biotech ......................................................................... 91

3

4

Wav

ebre

akm

edia

Mic

ro |

Fo

tolia

.co

m

Biotechnology – serving mankind and the environment

Man has been using microorganisms for thousands of years to make bread, wine and other

commodities. Biotechnology is not a new accomplishment; with the development of mod-

ern molecular biology, it has, however, experienced rapid proliferation. Today, bacteria,

yeasts and other living cells can be tailored so as to effect the large-scale production of

active pharmaceutical ingredients, chemicals and a great deal more besides. Also isolated,

microbially derived enzymes, too, are used in a number of industries as well as in everyday

processes, such as laundering.

Biotechnology is already pervading the most diverse industrial sectors. It is particularly in the

health, food and energy sector and is considered as a driver of innovation. For instance,

biotechnologically produced amino acids and vitamins increase the nutritional value of fod-

der and foodstuffs. In regenerative medicine, transplants replacing defective cartilage, skin

or other tissues undergo culture processes in the laboratory, where endogenous cells are

leveraged. Biotechnology also plays a critical role in the changeover from fossil raw materials

to renewable resources. Bioethanol, biogas and biohydrogen are generated from plant

residues and other organic waste. In future, the greenhouse gas carbon dioxide is even to

be transformed into base chemicals and other products with the aid of microorganisms. In

short: The potential of biotechnology is multifarious and far from being fully tapped.

Editorial

5

The biotechnology spectrum

Red and white biotechnology predominate in Hessen

The health sector continues to be the main driver of biotechnological innovation. Accord-

ingly, most Hessen-based companies engaged in this industry operate in the medical field

of red biotechnology. They focus upon new therapies and active ingredients, and upon

diagnostic procedures and tissue engineering.

In addition to this, more and more companies in Hessen are concentrating on white

biotechnology, also termed “industrial biotechnology”. The centrepiece thereby is consti-

tuted by designer cells or enzymes for the most diverse industries – from chemicals, through

textiles, right through to paper. While classical chemical procedures frequently necessitate

organic solvents, questionable chemicals and heat or other drastic conditions, biotechno-

logical processes are conducted at moderate temperatures, at ambient pressure and in

water. By contrast, green biotechnology, which is primarily concerned with the genetic opti-

misation of cultivated plants, plays a minor role in the biotech industry in Hessen.

Further biotechnology-related sectors in Hessen

The biotechnological spectrum does not confine itself to the colours red, white and green:

Yellow biotechnology seeks out substances or symbiotic microorganisms in insects that

can be used in medicine, agriculture or industrial processes. Grey environmental biotech-

nology, in its turn, develops procedures for water treatment, soil remediation, waste recy-

cling, exhaust air decontamination and exhaust emission purification. Some companies

engaged in this sector operate as service providers, suppliers or commissioned producers

of biomolecules in various biotechnological domains. In this era of “big data”, bioinformat-

ics companies, in particular, are assuming increasing importance. Whether it be genetic

analysis in medicine or the decoding of plant genomes: Bioinformatics holds the key to

the interpretation and secure management of data volumes.

Hessen: leading the field in biotechnology

Pioneers in biotechnology

Biotechnology has a long-standing tradition in Hessen. Emil von Behring, inventor of the

diphtheria vaccine, received the Nobel Prize for Medicine in 1901, establishing Behring-

werke AG in Marburg just a few years later – Hessen’s first biotechnology start-up, so to

speak. Similarly, at the beginning of the 20th century, Dr Otto Röhm isolated enzymes for

industrial leather bating for the very first time. Together with the merchant Otto Haas, he

founded the company Röhm & Haas (now known as Rohm & Haas), which, in 1909, relo-

cated to Darmstadt – close to the leather factories of the Rhine-Main region. The pioneering

achievements of Emil von Behring and Otto Röhm pervade the biotechnology landscape

of Hesse to this day. For instance, a significant network of red biotechnology companies

has developed out of the Behringwerke facility.

RG

timel

ine

| Fo

tolia

.co

m

Over the last few decades, a number of biotechnology companies have been established

in Hessen. They benefit from their proximity to industry giants, from the life sciences and

chemical sectors, which – likewise – are steeped in tradition. One such example is the oldest

chemical and pharmaceutical company in the world, Merck: In 1668, the Schweinfurt-based

pharmacist Friedrich Jacob Merck purchased a pharmacy in Darmstadt, as he was unable

to gain a foothold in his home town. This was the precursor of the global corporate group

that was ultimately established in 1827. Today’s Höchst Industrial Park also boasts a long

tradition: In 1863, Carl Friedrich Wilhelm Meister, Eugen Lucius and Ludwig August Müller

established the company Teerfarbenfabrik Meister, Lucius & Co. in Höchst, near Frankfurt.

In 1883, drug production commenced there and the company evolved into Hoechst AG,

one of the largest chemical and pharmaceutical companies in the world. In 1994, work com-

menced on the realignment and restructuring of Hoechst AG; the erstwhile main facility

was redeveloped, Höchst Industrial Park thus being established. The latter remains one of

the largest and most dynamic facilities within the chemical and pharmaceutical industry in

Europe. Then as now, the following holds true: Hessen offers scientists and companies with

its pioneering spirit ideal conditions for their commercial success.

Biotechnology in Hessen today

Hessen is home to more than 200 biotechnology companies. With a workforce of over

16,000 employees, they generate a yearly turnover of approximately twelve billion euros.

Close to 20 percent of the companies featured in this brochure employ more than 250

members of staff. Approximately a quarter of them are small companies with fewer than

ten employees. As a biotechnology hub, Hessen is distinct from others in that it is not only

characterised by innovative SMEs but also by established large and medium-sized phar-

maceutical and chemical companies, which do not only conduct biotechnological research

and development but which are also engaged in large-scale production.

7

Ale

xand

er R

ath

s |

Dre

amst

ime.

com

Traditionally, biotechnology in Hessen is pervaded by the state’s colours – red and white:

Almost 80 percent of the companies featured in the pages that follow focus upon the health

sector. The companies with the highest revenues include sanofi-aventis (now Sanofi), Merck

and AbbVie. Definitive for Hessen’s dynamism in the field of red biotechnology are, how-

ever, also innovative SMEs, such as Humatrix, Targos und Zedira. Similarly, in the sphere of

white biotechnology, a number of companies have operations in Hessen; these include

Evonik, BRAIN, N-Zyme BioTec and AB Enzymes. Over a third of the companies featured in

this Competence Atlas are engaged in the chemical sector, and over a quarter in the food

industry. Green biotechnology, on the other hand, is only sporadically represented both in

Hessen and across Germany. Companies like GenXPro, nadicom and LI-COR Biosciences

have operations that extend to this sector.

Hessen’s biotechnology industry is distinct in that it spans the entire value creation chain –

from research, through production, right through to distribution. Hessen accounts for close

to one third of the biotechnological production capacities of the entire country. Over half

of the companies in this Competence Atlas are engaged in production, and close to 60

percent in research and development. Almost 100 companies offer services, primarily in

the areas of consultancy, contract research and laboratory equipment.

8

Facilities with a synergistic effect

Industrial Parks in Frankfurt, Hanau, Wiesbaden and Marburg

In innovation-driven industries such as biotechnology, sustainable networks and inter-dis-

ciplinary cooperative alliances determine commercial success. Partnerships between the

scientific community and industry, and between start-ups and large corporations, are also

essential for swiftly implementing ideas in a practical setting. Hessen’s industrial parks and

incubator centres facilitate such cooperation by bringing those involved closer together in

geographical terms. Moreover, they offer young businesses, in particular, outstanding infra-

structure and, thus, conserve their resources.

Hessen has seven industrial parks: 16 companies are located at Behringwerke Marburg

Industrial Park, employing more than 5,000 persons in total. More than 70

companies with a total of over 5,500 employees are housed in

Kalle-Albert Industrial Park in Wiesbaden. Twelve compa-

nies are based at Wolfgang in Hanau Industrial Park,

which spans an area of 820,000 square metres.

Industrial parks are located in Frankfurt’s

Fechenheim, Griesheim and Höchst dis-

tricts. Höchst industrial park, housing

more than 90 companies and close to

22,000 employees, is the largest

chemical and pharmaceutical

industry facility in Hessen.

Kassel

Marburg

FuldaGießen

Frankfurt

Hanau

Darmstadt

Wiesbaden

9

Technology centres in Frankfurt, Gießen, Marburg and Pfungstadt

As a market-orientated technology hub, the Frankfurt Biotechnology Innovation Centre

(FIZ), established in 2002, offers SMEs from the domain of life sciences tailored infrastruc-

ture and facilitates access to cooperative alliance partners, inter-disciplinary networks and

markets. After the first two building phases achieved full occupancy, FIZ responded flexibly

to the high demand, commissioning a further 4,000 square metres in June 2014. Today, 16

companies with a total of 700 employees work on laboratory and office premises spanning

a total of 19,000 square metres. The Technology and Innovation Centre in Gießen (TIG), too,

which is considered to be a springboard to success for start-ups, leases out laboratory and

office facilities. Proximity to higher educational establishments in Middle Hessen, and being

located in the immediate vicinity of more than 80 innovative companies make for an optimal

foundation for cooperative alliances. TIG was derived from the Gießen incubator centre,

opened in 1996. In Marburg, young biotechnology companies have been drawing support

from the Technology Centre for Life Sciences (NTZ) since 2003. The NTZ provides modern

GMP, laboratory and office premises on a site spanning a total of 2,000 square metres.

Pfungstadt Biotech-Park, established by the town of Pfungstadt and R-Biopharm AG in 2013,

is a relative newcomer. Pfungstadt Biotech-Park, with 4,000 square metres of office space

and laboratories, offers premises for up to 10 companies and up to 100 employees.

Hessen: innovations on a solid foundation

Research and cooperation

Research is the bedrock of innovation. Along with the universities in Hessen, the numerous

extra-mural research institutions located here enjoy an excellent reputation on the global

stage. Four Max Planck Institutes (MPI) are setting benchmarks in fundamental biotechno-

logical research: the MPI for Heart and Lung Research in Bad Nauheim, the MPI for Terres-

trial Microbiology in Marburg, the MPI for Brain Research and the MPI for Biophysics, the

latter two being located in Frankfurt. The Georg-Speyer-Haus in Frankfurt and the Paul

Ehrlich Institute in Langen, which, in its capacity as a federal institution, is involved in

authorisation procedures for gene therapies and vaccines, carry out applied research in

red biotechnology.

The state of Hessen is aware of the significance of scientific grounding and promotes out-

standing research within the parameters of the state campaign for the Development of

Scientific and Economic Excellence (LOEWE). The state of Hessen supports thematically

focused research alliances between universities, technical colleges and extra-mural

research institutions in Hessen through the LOEWE centres. Thus, for instance, the LOEWE

Centre for Synthetic Microbiology (Synmikro) investigates fundamental characteristics of

cellular processes using synthetic and analytical research methodologies, and develops

procedures for equipping cells and cell components with novel functions. The LOEWE

Centre for Insect Biotechnology and Bioresources (ZIB) leverages the biodiversity of insects

at a molecular level to develop new active ingredients for applications in medicine, in sus-

tainable plant protection or in industrial biotechnology.

10

Oliv

ier

| Fo

tolia

.co

m

By contrast, LOEWE focal areas involve the pooling of selected key issues addressed in uni-

versities and extra-mural research institutions. The LOEWE focal area of Integrative Fungal

Research (IFR), for instance, is addressed by biodiversity researchers working in conjunction

with biochemists, biotechnologists and molecular geneticists: They aim to expand knowl-

edge of fungal diversity in Hessen and in selected tropical regions, and to identify new sub-

stances that could be used in industry, medicine and food production. In the LOEWE focal

area of medical RNomics, scientists consider the question as to how the expression of reg-

ulating ribonucleic acids changes during periods of human illness. The objective is to apply

the new findings to diagnostics and to translate them into new therapeutic concepts.

Furthermore, the “Funding Line 3: LOEWE-SME Collaborative Project” supports small and

medium-sized companies that aim to implement technology-orientated projects in con-

junction with partners from the world of science within a composite framework.

Company start-up made easy

The Germany-wide start-up initiative Science4Life, accorded financial support by the state

of Hessen and the pharmaceutical Group Sanofi, has established itself as one of the most

successful public-private partnerships for the promotion of company start-ups. Those who

participate in the business plan competition receive expert consultancy services free of

charge and can win cash prizes as well as the opportunity to participate in start-up work-

shops. Since its launch in 1998, Science4Life has resulted in approximately 600 company

start-ups.

Those wishing to transfer scientific findings to a practical setting can avail of consultancy

services both from universities and extra-mural technology transfer units in Hessen. The

transfer units identify trends and cooperative alliance partners. They also support targeted,

commercial positioning in the marketplace by providing information on patenting, licensing

and spin-offs.

11

Business development initiatives in Hessen

The Enterprise Europe Network

The Enterprise Europe Network (EEN) helps SMEs tap the European market. With close to

600 member organisations from more than 50 European countries – including chambers

of commerce and industry, technology centres, universities and business development

bodies – EEN is the largest European network of its kind. In conjunction with on-site part-

ners, EEN provides support to companies specific to expansion, technology transfer, finan-

cing, legal consultancy services and information services in the global context.

The Hessen-Biotech technology axis

Hessen-Biotech is the core biotechnology-specific information, communication and coop-

eration platform of the Hessian Ministry of Economics. The catalyst for this project is the

business development organisation Hessen Trade & Invest GmbH. Hessen-Biotech inte-

grates capabilities, promotes the capacity for innovation and the competitiveness among

Hessian companies and, thus, strengthens Hessen’s position as a centre of excellence in

biotechnology.

DragonImagess | Fotolia.com

12

mp

_im

ages

| F

oto

lia.c

om

13

Company Profiles

A–C ................................................................................................................................. 15

D–H ................................................................................................................................. 31

I–M ................................................................................................................................. 43

N–Q ................................................................................................................................. 54

R–Z ................................................................................................................................. 62

1414

Kad

my

| Fo

tolia

.co

m

15

AB Enzymes GmbH

CEO: Martin Klavs Nielsen

Feldbergstrasse 78D-64293 DarmstadtPhone +49 6151 3680-100Fax +49 6151 [email protected]

The Art of Enzymes: AB Enzymes is one of the world’s oldest and best known Enzyme companies. We offerenzymes for industrial applications worldwide. The prod-ucts range from food enzymes for baking and beveragesto enzymes for animal feed, textile technology and thedetergents industry. AB Enzymes’ focus in the biofuelmarket is in the use of lignocellulosic biomass to producetransport fuels.

The Company is represented in more than 50 countriesworldwide with headquarters in Darmstadt, Germany. Inaddition, there are also offices located in the US, Singa-pore, China and Brazil to serve you locally.

Business activities

ResearchDevelopmentProductionMarketingSales

ServicesAnalyticsIT, SoftwareLab equipmentCROTrainingsConsulting

Further

Applications

AgricultureChemistryDiagnosticsEngineeringEnvironmental ProtectionFood/FeedPharmaceuticals

Main field of biotechnology

Red BiotechGreen BiotechWhite BiotechNonspecific servicesBioinformatics

AbbVie GmbH & Co. KG

CEO: Richard A. Gonzalez

Mainzer Strasse 81D-65189 WiesbadenPhone +49 611 [email protected]

AbbVie is a global research-based biopharmaceuticalcompany formed in 2013 following separation fromAbbott Laboratories. The company’s mission is to use itsexpertise, dedicated people and a unique approach toinnovation to develop and market advanced therapiesthat address some of the world’s most complex and seri-ous diseases. AbbVie employs approximately 25,000people worldwide and markets medicines in more than170 countries.

For further information on the company and its people,portfolio and commitments, please visit www.abbvie.com.Follow @abbvie on Twitter or view careers on our Face-book or LinkedIn page.

Business activities



Further

Applications




16

ABT Armbruster Biotechnologie GmbH

CEO: Dr. Franz Paul Armbruster

Stubenwald-Allee 8aD-64625 BensheimPhone +49 6251 701900Fax +49 6251 849430info@armbruster-biotechnology.comwww.armbruster-biotechnology.com

Founded in 2001, Armbruster Biotechnology GmbH is aresearch company engaged mainly in the areas of bonemetabolism and bone metastases. Together with partnersfrom other research institutes and clinics, ABT studiesbone matrix proteins used in tumor therapy, particularlyagainst bone metastases.

Armbruster Biotechnology provides other research com-panies with cell lines, antibodies, recombinant antigensand immunoassays developed by the company as part ofits own research activities.

Business activities



Further

Applications




Accovion GmbH

CEO: Dr. Andree Beckerling

Helfmann-Park 10D-65760 EschbornPhone +49 6196 7709-0Fax +49 6196 [email protected]

Accovion, headquartered in Frankfurt (Eschborn), Ger-many, is a leading independent European full-serviceContract Research Organization. The company providesthe entire range of clinical research services to the phar-maceutical, biotechnology and medical device industriesand is currently active in more than 20 countries.

For more than 10 years, Accovion has been successfullyconducting national and international clinical trials acrossall phases of clinical development. Accovion’s localexpertise in offices across Europe, combined with broadexperience, enables it to deliver the support that clientsneed, where and when needed. Accovion is known for itspremium quality front-end and back-end services in earlyto late phase development, as well as Post Market Surveil-lance (PMS). Quality, reliability and flexibility are the val-ues that clients can expect from Accovion.

Business activities



Further

Applications




17

AdiuTide Pharmaceuticals GmbH

CEO: Dr. Eugen Uhlmann

Alt Fechenheim 34D-60386 Frankfurt am MainPhone +49 69 42603731Fax +49 69 41674770contact@adiutide-pharmaceuticals.comwww.adiutide-pharmaceuticals.com

AdiuTide Pharmaceuticals GmbH is a biopharmaceuticalcompany which discovers and develops novel nucleicacid-based therapeutics to treat a number of diseasesincluding cancer, infectious diseases, asthma and aller-gies, and for use as vaccine adjuvants. The Company hasestablished a broad intellectual property position basedon immune modulatory oligonucleotides, in particularToll-like Receptor 9 (TLR9) Agonists and Retinoic Acid-Inducible Gene I (RIG-I) ligands as well as immuneinhibitory oligonucleotides (TLR9 antagonists).

The most advanced candidate of AdiuTide is the TLR9agonist ATP00001 to be developed as adjuvant in com-bination with a tumor antigen. It is currently subject topre-clinical studies and the company plans to start aPhase 1 study in tumor patients by Q1/2015.

Business activities



Further

Applications




Advanced Cyclotron Systems GmbH

CEO: Richard Eppich

Im Leuschnerpark 2aD-64347 GriesheimPhone +49 152 [email protected]

Advanced Cyclotron Systems, Inc. (ACSI) is a world leaderin the design and manufacturing of cyclotron equipment,including PET and SPECT radioisotope productioncyclotrons. We manufacture and supply complete sys-tems for radioisotope and radiocompound production.

ACSI has been in business for over 20 years and we arebacked by our affiliated company EBCO Industries, whichis one of Canada’s largest manufacturing facilities withover 50 years in manufacturing expertise. Our dedicatedteam of professionals, scientists and engineers is proudto deliver quality workmanship, on-time delivery, andtechnological advancements for the industry.

Business activities



Further

Applications




18

Aeterna Zentaris GmbH

CEO: Dr. Richard Sachse

Weismuellerstrasse 50D-60314 Frankfurt am MainPhone +49 69 42602-3228Fax +49 69 [email protected]

Aeterna Zentaris GmbH, located in Frankfurt am Main, isa wholly owned subsidiary of the Canadian companyAeterna Zentaris Inc., Quebec City. Aeterna Zentaris is aspecialty biopharmaceutical company engaged in devel-oping novel treatments in oncology and endocrinology.It’s pipeline encompasses compounds at various stagesof development.

The company has submitted a New Drug Application(NDA) to the US FDA for its ghrelin agonist, macimorelinacetate in November 2013. A pivotel phase 3 study withour targeted drug conjugate zoptarelin doxorubicin inendometrial cancer is ongoing. Aeterna Zentaris is in atransition process from an R&D driven company into acommercially operating company.

Business activities



Further

Applications




Alcedis GmbH

CEOs: Dr. Elke Heidrich-Lorsbach Michael Lorsbach

Winchesterstrasse 3D-35394 GiessenPhone +49 6419 4436-0Fax +49 6419 [email protected]

Alcedis GmbH stands for long years of CRO experienceand profound expertise in the conduct of clinical trials.Our innovative software systems constitute a centrepieceof the Alcedis trademark.

Our module-based service concept adjusts itself flexiblyto your project structure. Likewise, our data entry andsoftware systems are individually adapted.

With our network of qualified partners, we conductnational or international phase I to IV multi-center studies,non-interventional studies and registers for medicinalproducts and medical devices.

In short: We are your competent partner for the conductof your clinical studies – active worldwide and yet “underone roof”!

Business activities



Further

Applications




19

AlphaScience GmbH

CEO: Ludger Gollan

Hauptstraße 54D-64560 RiedstadtPhone +49 6158 74804-0Fax +49 6158 [email protected]

AlphaScience GmbH is a Germany based, integrated lifescience company established in 2004 as a co-manufac-turer, distributor and supplier of quality DiagnosticReagents, Kits and Service. The company markets itsproducts and technologies to hospitals, reference labo-ratories, research centers, diagnostics manufacturers, andbiotech companies in Germany through direct sales forceand in Europe through independent distributors.

Our Key competence is in detection of Infectious Dis-eases, Autoimmune, Allergy and Research Reagents byvarious methods like ELISA, IFT/ DFT, POC and PCR fromwell-known companies with best reputation.

Business activities



Further

Applications




Analyticon Biotechnologies AG

CEO: Wolfgang Meyer

Am Muehlenberg 10D-35104 LichtenfelsPhone +49 6454 7991-0Fax +49 6454 7991-30info@analyticon-diagnostics.comwww.analyticon-diagnostics.com

Analyticon Biotechnologies AG is a world leader in devel-oping and manufacturing diagnostic systems. The prod-ucts provide healthcare professionals with accurate andaffordable diagnostic solutions in physicians’s offices,hospitals and clinical laboraties. Analyticon is focused onfour business lines: clinical chemistry, coagulation, hema-tology and urine diagnostics. Within those lines the com-pany offers a broad and leading range of urine test strips,clinical chemistry parameters, hematology and coagula-tion reagents.

The product lines are complemented by various cutting-edge analyzers for different throughputs. The systems aredistributed in nearly 100 countries all over the worldthrough a strong distributor network. The company’s suc-cess is based on its ambitious customer support concep-tion including thorough training programs for field ser-vice engineers, application specialists and sales staff.

Business activities



Further

Applications




20

anamed Elektrophorese GmbH

CEO: Thomas Heisel

Ringstrasse 4D-64401 Groß-BieberauPhone +49 6162 80984-0Fax +49 6162 [email protected]

anamed Elektrophorese GmbH’s historical background isthe experience of more than 10 years of production anddistributionship for 10 cm x 10 cm vertical pre-cast gelsalong with other consumables for the electrophoresis labsuch as buffers, stainers, standards, gel drying solutionand of course electrophoresis instruments as well.

Business activities



Further

Applications




AXIOM GmbH

CEO: Dr. med. Wolfgang Hypko

Am Jahnplatz 5D-68642 BürstadtPhone +49 6206 6012Fax +49 6206 [email protected]

AXIOM Gesellschaft für Diagnostica & Biochemica mbHis based in Bürstadt with a branch in Worms. Our brandname AXIOM has been introduced in more than 80 coun-tries incl. all of Europe and is one of the leading manu-facturer and a worldwide direct supplier and exporter ofClinical Chemistry, Microwell ELISA Systems and productsincl. Infectious Diseases HIV, HCV, HBsAg, HEV and otherparameters, Coagulation and Haematology with Reagents,Rapid Tests, Serology, Urine Analysis, Lab Instruments andMicroscopes for Laboratory, Hospitals as well as Universi-ties and Schools. AXIOM has experience of in-vitro andlaboratory diagnostics including automated system solu-tions. Our customers include top distribution companies,Hospitals, Industrial, Educational, Governmental organi-zations and also end-users. Our company’s success isbased on its ambitious customer support concept provid-ing technical support, innovative product information andlogistics.

Business activities



Further

Applications




21

BAG Health Care GmbH

CEO: Dr. Nicolas Sachsenberg

Amtsgerichtsstrasse 1-5D-35423 LichPhone +49 6419 25-0Fax +49 6419 [email protected]

BAG Health Care GmbH is a family-run health care com-pany which develops, manufactures and markets in-vitrodiagnostics and hygiene monitoring products. Its in-vitrodiagnostics product line focuses on transplant diagnos-tics and blood group typing. The hygiene monitoringbusiness area comprises manufacturing and distributionof sterilization, disinfection and cleaning efficiency tests.As a contract manufacturer for the pharmaceutical indus-try, BAG specializes in parenteral rugs. We have thecapacity for pilot projects, clinical test substances andcommercial products and we support customers in PhaseI-III clinical trials through upscaling and production, rang-ing from validation batches to commercial products.Clean room clusters allow flexible synthesis of substancesin compliance with GMP guidelines.

Business activities



Further

Applications




BCNP Consultants GmbH

CEO: Dr. Holger Bengs

Varrentrappstrasse 40-42D-60486 Frankfurt am MainPhone +49 69 6199 42-73Fax +49 69 6199 [email protected]

BCNP offers specialized consulting services in biotech,chemistry, nanotech and pharma (BCNP).BCNP services areas are:

a 1. Technology Strategy a 2. Market Intelligencea 3. Marketing Management a 4. Capital Sourcing

Clients benefit from BCNP’s comprehensive scientificexpertise in chemistry, biochemistry, biology and biotech-nology. The team is completed by a financial expert andan international marketing specialist. BCNP consultantsunderstand the technical/scientific and economicalneeds of their clients. The spectrum of clients ranges fromuniversities and NGOs to SMEs and big publicly tradedcompanies. BCNP is very well connected to experts anddecision makers in various industries. Since 2010, BCNPhas been authorized by the Federal Ministry of Econom-ics and Technology (BMWi) in the program BMWi-Inno-vationsgutscheine (go-Inno).

Since 2010, BCNP has been authorized by the FederalMinistry of Economics and Technology (BMWi) in the pro-gram BMWi-Innovationsgutscheine (go-Inno).

Business activities



Further

Applications




22

Biaffin GmbH & Co KG

CEO: Dr. Bastian Zimmermann

Heinrich-Plett-Strasse 40D-34132 KasselPhone +49 561 8044-668Fax +49 561 [email protected]

Biaffin GmbH & Co KG is a bioanalytical service provider specialized in sur-face plasmon resonance (SPR) for biomolecular interaction analysis tokinetically characterize any pair of interacting molecules in real-time in alabel-free state. Biaffin has more than 12 years of experience in developingcustomized projects for drug development programs of pharma, biotech,generic drug companies and scientific institutions worldwide. Our highlyspecialized team uses state of the art SPR instruments (Biacore) in an IS09001:2008 certified lab.

Biaffin’s SPR services comprise hit validation, secondary screening and leadoptimization of small molecule drugs as well as kinetic characterization,mechanism of action and thermodynamics, stability, quality control andbatch to batch comparison of antibodies, biologics and biosimilars. Bio-chemical and enzymatic assays based on microfluidic mobility shift tech-nology, bioluminescence and spectrophotometry complement our serviceportfolio. Biaffin’s online shop Proteinkinase.biz offers high-quality prod-ucts for kinase research and signal transduction (kinases, phosphatases,cytokines, receptors, substrates, inhibitors, antibodies, kinase assays).

Business activities



Further

Applications




Biebertaler Blutegelzucht GmbH

CEO: Harald Th. Galatis

Talweg 31D-35444 BiebertalPhone +49 6409 661 40-0Fax +49 6409 661 [email protected]; www.bbez.de

Biebertaler Blutegelzucht was established in Biebertal in1991 and is now the leading producer of leeches formedical applications in the EU. A focal area of its businessis breeding the Hirudo verbana / medicinalis /orientalisspecies and placing them on the market for medical use.

The company also trains physicians and other medicalpersonnel in leech therapy, and publishes scientific information on the biology of leeches, therapeuticapproaches and active ingredients. Finally, its portfolioincludes products for the care of leeches for medical use.In order to improve the knowledge about leeches andleech therapy we cooperate with several universities andclinics.

Business activities



Further

Applications




23

bio.logis GmbH

CEO: Prof. Dr. med. Daniela Steinberger

Altenhöferallee 3D-60438 Frankfurt am MainPhone +49 69 5308 437-0Fax +49 69 5308 [email protected]

bio.logis Genetic Information Management develops IT-solutions for the management of genetic data and relatedscientific content (GIM) based on its comprehensiveexpertise in Human Genetics. GIM enables interestedpersons and physicians to use genetic data for personaldecision making and clinical purposes. bio.logis focuseson genetic information that is useful for improving health,e.g. by adjusting lifestyle or medications. We do not pro-vide irrelevant genetic information.

The bio.logis team consists of expert physicians, scien-tists, technicians, IT experts and economists. Prof. Dr.med. Daniela Steinberger is medical director of bio.logis.She is a specialist in Human Genetics and has 20 years ofexperience in human genetic diagnosis.

Business activities



Further

Applications




bioactiva diagnostica GmbH

CEO: Adnan Dawoud

Louisenstrasse 137D-61348 Bad HomburgPhone +49 6172 17102-0Fax +49 6172 [email protected]

bioactiva diagnostica GmbH is specialized in producingand distributing in-vitro diagnostics, lab-ware and med-ical equipment. We offer high-quality products at moder-ate prices.

Business activities



Further

Applications




24

biomedis Laborservice GmbH

CEO: Klaus Fey Thomas Pillich

Kerkrader Strasse 2D-35394 GießenPhone +49 6419 46001-0Fax +49 6419 [email protected]

biomedis Laborservice GmbH provides services forbiotechnological, biological and medical laboratoriesthroughout Germany. The offering includes the inspec-tion of microbiological safty cabinets and the mainte-nance and repair of laboratory equipment.

Biomedis is accredited under DIN EN ISO/ITEC 17025 totest the instruments used to messure pressure and tem-perature on autoclaves, sterilizers, incubators and cali-brate pipettes, burettes and dispensers. In addition to itstechnical services, biomedis offers a range of laboratoryequipment and, if requested, training programs for indi-vidual customers or applications.

Business activities



Further

Applications




BioSciTec GmbH

CEO: Dr. Robert Jaeger

Westerbachstrasse 47D-60489 Frankfurt am MainPhone +49 69 4208 2884Fax +49 69 4208 [email protected]

BioSciTec GmbH develops, manufactures and marketsimaging solutions for bio-sciences, including systems for(semi-)automated analysing of test strips, rapid tests andcolony counting.

After starting off with electrophoresis gel documentation,we entered into laboratory diagnostics in 2001 with thedevelopment of the “BLOTrix” software for reading infec-tious disease test strips. Only a few years later, opticalreading devices became as important to us as the pro-duction of software, applying an ISO 13485 certified qual-ity management system.

Today, automated diagnostic strip reading is hardly ima-ginable without BioSciTec GmbH. Cooperating with themajor test strip manufacturers worldwide, we reached aleading market position in 2007. In Frankfurt we are work-ing with an interdisciplinary team of biologists, mathemati-cians, software developers and image processing experts.

Business activities



Further

Applications




25

BioSpring GmbH

CEO: Dr. Sylvia Wojczewski

Alt-Fechenheim 34D-60386 Frankfurt am MainPhone +49 69 408 07222Fax +49 69 408 [email protected]

BioSpring is a cGMP and ISO 13485 certified specialistmanufacturer of therapeutic, diagnostic and researcholigonucleotides and a provider of analytical servicesrelated to oligonucleotides. BioSpring accompanies pro-jects in the olinucleotide field from early research to themarketing phase employing efficient manufacturing andanalytical technologies.

BioSpring supports its customers worldwide to efficientlydevelop their oligonucleotide products. BioSpring is aprivately owned company with headquarter in Frankfurt,Germany, that has been providing services to theoligonucleotide industry for more than 17 years.

Business activities



Further

Applications




Biotec-Fischer GmbH

CEO: Michael Fischer

Daimlerstrasse 6D-35447 ReiskirchenPhone +49 6408 6072Fax +49 6408 [email protected]

Biotec-Fischer GmbH is a manufacturer and distributor ofelectrophoresis equipment for scientific and clinicalapplications. In addition, the sales program contains geldocumentation systems and densitometry software spe-cially designed for routine clinical and scientific applica-tions such as 1D and 2D electrophoresis.

Another area of business comprises chemicals, reagentsand consumable kits for clinical electrophoresis applica-tions. The sales program is rounded out by a wide rangeof analytical instruments such as UV/VIS spectrophotome-ters, HPLC, GC and AAS.

Business activities



Further

Applications




26

BIT Analytical Instruments GmbH

CEO: Marius Balger

Am Kronberger Hang 3D-65824 SchwalbachPhone +49 6196 806-100Fax +49 6196 [email protected]

BIT Analytical Instruments is part of the BIT group com-panies. BIT provides OEM services for complex IVD, med-ical and life science instruments and compact medicalappliances. Its portfolio comprises complete productdevelopment, design, contract manufacturing and after-sales service for appliances used in clinical diagnostics,life sciences and biotechnology.

Its technology platforms allow the integration ofequipement of varying sizes and configurations for arange of diagnostic processes. BIT’s solutions are avail-able worldwide. The company is ISO 9001 and ISO 13485compliant and is a FDA-registered contract service-provider.

Business activities



Further

Applications




Bochem Instrumente GmbH

CEO: Jürgen Bochem

Industriestrasse 3D-35781 WeilburgPhone +49 6471 9282-0Fax +49 6471 [email protected]

Bochem Instrumente GmbH was established in 1957 andhas been a leading manufacturer of metal goods andinstruments for laboratory requirements since 1957. Thecompany has state-of-the art production equipment. Theentire production program manufactured by its experi-enced production workers is directly available from itswarehouse. Orders can be shipped to its internationalcustomers without any delay.

The product portfolio includes frames and clamps, labjacks, containers, gas burners, wire products, laboratoryfurniture and tools. Customized production is availableon request. Alongside manufacturing techniques involv-ing various metals, Bochem specializes in stainless steelproducts and is now a leading supplier of such productsfor laboratory use.

Business activities



Further

Applications




27

BRAIN AG

CEO: Dr. Holger Zinke

Darmstädter Strasse 34-36D-64673 ZwingenbergPhone +49 6251 9331-0Fax +49 6251 [email protected]

BRAIN AG is an industrial “white” biotech company which discovers anddevelops novel bioactive natural compounds and proprietary enzymes forits partners and customers in the chemical and pharmaceutical industriesas well as the food and cosmetics industries. With its unique approach tothe discovery and production of new biological compounds and biocata-lysts, the company achieves creative solutions by harnessing nature’suntapped biodiversity. Its success is built on its proprietary BioArchive com-prising millions of genes, proteins and metabolic pathways from microbialisolates and metagenome libraries. Since its foundation in 1993, BRAINhas entered into over 80 strategic partnerships and alliances with nearlyall the relevant companies within the chemical industry, for example BASF,Ciba, Clariant, Evonik, DSM, Genencor, Henkel, Nutrinova, RWE, Sandoz,Schering, Südzucker and Symrise, to name but a few. BRAIN currentlyemploys 114 highly skilled people. For their groundbreaking industrialbiotechnology activities for a sustainable “biologisation of the chemicalindustry” using nature’s toolbox for industrial processes, BRAIN and its CEO Dr. Holger Zinke received the “Deutschen Umweltpreis 2008” of the“Deutsche Bundesstiftung Umwelt”, DBU.

Business activities



Further

Applications




Capricorn Scientific GmbH

CEO: Harry Brack

Auf der Lette 13AD-35085 EbsdorfergrundPhone +49 6424 94464-0Fax +49 6424 94464-20info@capricorn-scientific.comwww.capricorn-scientific.com

Capricorn Scientific is a newly established company whichis expected to set a new standard in the field of cell cul-ture. We specialize in the manufacture and worldwide dis-tribution of cell culture products for research, develop-ment, diagnostic and biopharmaceutical production. Thecompany manufactures products for the cultivation, stor-age and separation of cells. Our team of highly skilled andexperienced specialists has been working in the field ofcell culture for many years. We are committed to provid-ing high quality, reliability, and the service you have cometo expect from a globally active cell culture company. Themission of Capricorn Scientific is to provide quality cellculture media components, products, and services usingthe highest safety and compliance standards, to meet theneeds of our customers in the global bioprocessing andclinical diagnostic industries. Capricorn Scientific pro-duces a range of fetal bovine serum and other sera, pro-tein fractions, and cell culture media supplements.

Business activities



Further

Applications




28

Cepheid GmbH

CEO: Daniel Hefel

Unterlindau 29D-60323 Frankfurt am MainPhone +49 69 7104 800Fax +49 69 2551 [email protected]

Based in Sunnyvale, California, Cepheid is a leadingmolecular diagnostics company that is dedicated toimproving healthcare by developing, manufacturing, andmarketing accurate yet easy-to-use molecular systemsand tests. By automating highly complex and time-con-suming manual procedures, the company’s solutionsdeliver a better way for institutions of any size to performsophisticated genetic testing for organisms and genetic-based diseases.

Through its strong molecular biology capabilities, thecompany is focusing on those applications where accu-rate, rapid, and actionable test results are needed most,such as managing infectious diseases and cancer. Formore information, visit www.cepheidinternational.com.Since 2007 German customers can benefit from our prod-ucts. In 2012, Cepheid GmbH was founded inFrankfurt/Main.

Business activities



Further

Applications




Chemgineering Technology GmbH

Kreuzberger Ring 13D-65205 WiesbadenPhone +49 611 77887-0Fax +49 611 [email protected]

The Chemgineering Group provides first-class and well-proven consultingand engineering services to the highly GxP-regulated life sciences indus-tries, including pharmaceuticals and biotechnology. The TechnologyDesigners handle investment projects within all disciplines. Technologydesign at Chemgineering encompasses the conceptual phase, basic anddetailed design as well as the processing and qualification of small orsophisticated large-scale projects. This comprises the planning and imple-mentation of plants including upgrades and construction of productionplants, development and research centers, facilities to sustain infrastruc-tures or complete factories. In this regard, the company acts primarily as ageneral planner. The Business Designers provide consulting services inde-pendent from investment projects: Management Consulting ranges frombusiness process management, process optimization up to investment con-sulting. Compliance Consulting is concerned with implementation of reg-ulatory requirements in the fields of pharmaceuticals, medical devices andother industries. Information Systems Consulting covers the entire processof computerized systems validation.

Business activities



Further

Applications




29

Chugai Pharma Germany Ltd.

CEO: Osamu Nagayama

Lyoner Strasse 15D-60528 Frankfurt am MainPhone +49 69 6630 00-0Fax +49 69 6630 [email protected]

Chugai Pharma Germany is the local affiliate of ChugaiPharmaceuticals, located in Tokyo, Japan, member of theRoche Group. In Germany, we provide high-qualitybiotech pharmaceuticals in the areas of oncology / sup-portive care and rheumatology / immunology as well assuperior services for patients and all stakeholders inhealthcare. We are dedicated to continuously developingbetter treatment options by high investments into ourstrong global research activities in our core indicationareas.

Business activities



Further

Applications




CIRI GmbHCentre of Innovative Diagnostics and TherapeuticsRheumatology, Immunology

CEO: Dr. Frank Behrens

Sandhöfer Allee 6D-60528 Frankfurt am MainPhone +49 69 6301-7302Fax +49 69 [email protected]

Clinical Research in the field of rheumatology, immunol-ogy

Business activities



Further

Applications




30

CSL Behring GmbH

CEOs: Dr. Roland Martin, Berthold Süsser, Matthias Kutz

Emil-von-Behring-Strasse 76D-35041 MarburgPhone +49 6421 39-12Fax +49 6421 [email protected]

CSL Behring is a leader in the plasma protein therapeu-tics industry. Committed to saving lives and improvingthe quality of life for people with rare and serious dis-eases, the company manufactures and markets a rangeof plasma-derived and recombinant therapies worldwide.CSL Behring therapies are indicated for the treatment ofcoagulation disorders including hemophilia and vonWillebrand disease, primary immune deficiencies, hered-itary angioedema and inherited respiratory disease.

The company’s products are also used in cardiac surgery,organ transplantation, burn treatment and to preventhemolytic diseases in newborns. CSL Behring operatesone of the world’s largest plasma collection networks,CSL Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company headquartered in Mel-bourne, Australia.

Business activities



Further

Applications




Cyntegrity Germany GmbH

CEO: Dr. Artem Andrianov

Talstrasse 4D-65719 HofheimPhone +49 6192 470 113-50Fax +49 6192 470 [email protected]

Cyntegrity offers services and systems for efficient risk-based monitoring of a clinical trial. We offer a risk man-agement process through a data-driven software systemwhich provides you a 100 % control of your clinical trial.Long experience of our employees in data analysis in dif-ferent clinical studies allowed us to identify early risk indi-cators for major risk factors. For instance, protocol non-compliance, patient dropouts and technical defects ofEDC software, etc. The essence of our knowledge is con-centrated in our systems and services. They enable a saferand more cost efficient monitoring process of your trial.

Core competencies:a Integrated Risk Based Monitoringa Monitoring Software for clinical trialsa Data Analysis a Data Mining & Big Data

Contact us for the free evaluation of the cost reductionplan of your trial monitoring.

Business activities



Further

Applications




31

CytoTools AG

CEO: Dr. Mark-André Freyberg

Klappacher Strasse 126D-64285 DarmstadtPhone +49 6151 9515-812Fax +49 6151 [email protected]

CytoTools AG is a biotechnology company focused ontranslating fundamental biology research on the mecha-nism of cell growth and programmed cell death intounique therapies that are designed to treat the cause ofthe disease rather than the symptoms.

The Company’s business strategy is to advance its thera-peutic candidates to a stage where they can be part-nered, licensed or sold to international pharmaceuticalcompanies for further clinical development or globalmarketing. CytoTools has an extensive and broad patentportfolio that covers its know-how and therapeutic assetsworldwide.

Business activities



Further

Applications




Danico GmbH

CEO: Dipl.-Biol. Arian Nek

Im Herrnwald 1cD-65779 KelkheimPhone +49 6195 97 61734Fax +49 6195 97 [email protected]

Danico GmbH develops and distributes climate-friendlyLubricants which are made of renewable resources, andspecial cosmetics for sport. Our product range includeslubricants for chains, shock absorbers, hydraulicmachines, brake fluids and medical devices. Togetherwith our cooperation partners, we currently offer a broadrange of eco-certified and energy-efficient high-perfor-mance bio-lubricants and cooling agents.

Aims in the development of our biotech lubricants are theprotection of water resources respectively for fauna andflora, the avoidance of carbon dioxide emissions andreduction of dependence on oil. Our products enablesuccessful implementation of bio-economy in manufac-turing industry.

Business activities



Further

Applications




32

Dentons LLP

CEO: Elliott Portnoy

Platz der Einheit 2, Gebäude PolluxD-60327 Frankfurt am MainPhone +49 69 4500 12-0Fax +49 69 4500 [email protected]

Dentons is a new global law firm driven to provide you with the competitiveedge in an increasingly complex and interconnected marketplace. Dentonsis built on the solid foundations of three highly regarded law firms: SalansLLP, Fraser Milner Casgrain (FMC) LLP and SNR Denton. Our approximately2,600 lawyers and professionals in more than 75 locations across 50-pluscountries are dedicated to providing you with consistent high-quality serv-ice wherever you do business. In Germany, in our two offices in Berlin andFrankfurt/Main, we advise you in all key areas of business and commerciallaw.

Dentons’ Life Sciences experts in Germany advise on project-related trans-actions, or alternatively as an “outsourced legal department”, with deepindustry-specific knowledge, creativity and years of expertise to ensuretheir clients’ success. Whether licensing contract deals or regulatory issuesrelating to the drug advertising law, as part of a team of over 80 lawyersand tax consultants in Germany, Dentons provides companies in the areasof pharmaceuticals, diagnostics, biotechnology and medical devices witha future-oriented and interdisciplinary legal advice.

Business activities



Further

Applications




Diagnostics Biochem Deutschland GmbH

CEO: Manon Hogue

Winchester Strasse 2D-35394 GießenPhone +49 6419 72177-0Fax +49 6419 [email protected]

Innovation Diagnostics Biochem Deutschland GmbH isdeveloping and marketing unique immunoassay kits. Asa manufacturer of high quality immunoassays for a globalmarket, we are constantly looking for new technologiesand applications that can lead to an improvement in thediagnosis of diseases and ultimately of the quality of lifeof people around the world.

Quality DBC is committed to providing extraordinaryquality in the development and manufacturing of ourproducts. We will continue to develop and manufactureour products with quality compliance to all applicableregulatory requirements along with continued improve-ment and customer satisfaction. ISO 9001/13485 Regis-tered, Health Canada, FDA and CE certificates.

Business activities



Further

Applications




33

DRG Diagnostics GmbH

CEO: Wilhelm Sänger

Frauenbergstrasse 18D-35039 MarburgPhone +49 6421 1700-0Fax +49 6421 [email protected]

Founded in 1970, DRG is a multi-national specialty med-ical equipment and diagnostics manufacturer and distrib-utor with successful representation in over 110 countriesthrough a network of DRG subsidiaries and local distrib-utors.

The German division, DRG Instruments GmbH, foundedin 1973, is located in Marburg and specializes in thedevelopment and the production of innovative ELISASand Chemiluminescent assays for both routine andresearch applications in the fields of diabetes diagnosis,endocrinology, prenatal / neonatal supervision, thyroidfunction and many more. At the end of 2008, DRG begandeveloping a closed system, its DRG:HYBRiD.XL, a fullyautomated analyzer for the simultaneous determinationof immunoassays as well as clinical chemistry.

Business activities



Further

Applications




eBioscience GmbH –an Affymetrix company

CEO: Dr. Irene Rech-Weichselbraun

Eysseneckstrasse 4D-60322 Frankfurt am MainPhone +43 179 640 40-305Fax +43 179 640 [email protected]

eBioscience, an Affymetrix company, is a leading providerin the area of flow cytometry. We offer a broad range ofantibodies and fluorochromes for scientific research inthe Life Sciences. Another focus in our portfolio are clas-sical as well as bead-based multiplexed immunoassaysfor the quantification of cytokines, growth factors and sol-uble proteins. Additional to assays for the quantificationof proteins, we also offer reagents for RNA detection.

Each year, the company develops more than 800 inno-vative products for scientific research in immunology,oncology, cell biology and stem cell biology.

Business activities



Further

Applications




34

Elementar AnalysensystemeGmbH

CEO: Dr. Hans-Peter Sieper

Donaustrasse 7D-63452 HanauPhone +49 6181 9100-0Fax +49 6181 [email protected]

Elementar Analysensysteme GmbH, a spin-off from theanalytic technology division of Heraeus, is a major pro-ducer of devices for analyzing non-metallic elementssuch as carbon, nitrogen, sulfur, hydrogen and oxygen.The company specializes in devices for CHNOS elemen-tal analysis, nitrogen/protein analysis, and TOC/TNbanalysis for micro and macro samples. The field of non-metallic analysis is rounded off by special attachmentsand additional units. Our product range, which isdesigned to offer complete problem solutions for users,is backed up by a wide variety of accessories and con-sumables. The product range also includes instrumentsfor the mass spectrometrical measurement of isotoperelations (IRMS) of stable isotopes 15N, 13C, 34S, 18O or2H in connection with elemental analysis (E/A) for appli-cations in the general soil and plant research, but also forthe investigation of origin, quality or falsification of foodsuch as meat, dairy products or wine.

Business activities



Further

Applications




Engelhard Arzneimittel GmbH & Co. KG

CEOs: Georg Maximilian Engelhard, Oliver Engelhard,Richard Mark Engelhard, Dr. Rolf Engelhard

Herzbergstrasse 3D-61138 NiederdorfeldenPhone +49 6101 539-300Fax +49 6101 [email protected]

Engelhard Arzneimittel GmbH & Co. KG is a modern,medium-sized pharmaceutical company based in theRhein-Main region. The company was founded in 1872.Its product range mainly comprises respiratory tract ther-apeutics and pharmaceutical products for the treatmentof various skin diseases, including established phytophar-maceuticals especially for the pediatric practice.

The company’s products hold a market-leading positionin the field of the OTC business in Germany and abroad.Through permanent target-oriented research with inno-vative product development, Engelhard has become anefficient pharmaceutical manufacturer, standing for high-quality pharmaceuticals. Engelhard Arzneimittel exportsto markets on all continents.

Business activities



Further

Applications




35

Ergomed Group GmbH

CEO: Dr. Miroslav Reljanovic

Otto-Volger-Strasse 9bD-65843 Sulzbach/TaunusPhone +49 6196 90754-0Fax +49 6196 [email protected]

ERGOMED is a worldwide clinical development companywith headquarter in Guildford, UK. While experienced ina wide variety of indications, ERGOMED specializes in thefields of oncology, neurology, immunology and rare dis-eases.

ERGOMED delivers excellent performance through theuse of its unique study Site Management model andStudy Physician Support. ERGOMED has a 15-year trackrecord of successfully managing clinical developmentsfrom Phase I through to late phase programs.

ERGOMED has been involved in more than 70 substancedevelopments with biotech and pharma companiesaround the globe resulting in the successful registrationof many substances at more than 1000 sites worldwide.

Business activities



Further

Applications




Bernd Euler Biotechnologie – Mikrobiologie

CEO: Bernd Euler

PF. 600391D-60333 Frankfurt am MainPhone +49 69 4288 793Fax +49 69 4080 [email protected]

Bernd Euler Biotechnology Mikrobiologie – Geräte undVerbrauchsmaterialien is producing and distributingdevices for microbiological cell disruption. The companywas founded in 1996. Marketing activities are focused pri-marily on Germany, though in individual cases transac-tions are carried out on a European or worldwide basis.

Bernd EulerBiotechnologie – Zellaufschluss

Business activities



Further

Applications




36

Evonik Industries AG

CEO: Dr. Klaus Engel

Rodenbacher Chaussee 4D-63457 Hanau-WolfgangPhone +49 201 177-01Fax +49 201 [email protected]

Evonik, the creative industrial group from Germany, is oneof the world leaders in specialty chemicals. Profitablegrowth and a sustained increase in the value of the com-pany form the heart of Evonik’s corporate strategy. Itsactivities focus on the key megatrends health, nutrition,resource efficiency and globalization. Evonik benefitsspecifically from its innovative prowess and integratedtechnology platforms. Evonik is active in over 100 coun-tries around the world.

In fiscal 2013 more than 33,000 employees generatedsales of around € 12.9 billion and an operating profit(adjusted EBITDA) of about € 2.0 billion. Evonik serves thebioeconomy markets with products such as feed aminoacids Biolys®, ThreAMINO®, TrypAMINO® or bio-basedpolymers DYNACOLL® Terra, DYNAPOL® Terra, VES-TAMID® Terra.

Business activities



Further

Applications




Fiebig – Nährstofftechnik

CEO: Reinhard Fiebig

Brunnenstrasse 26D-65510 Idstein-NiederauroffPhone +49 6126 52813Fax +49 6126 54988Fiebig-Naehrstofftechnik@T-Online.dewww.fiebig-naehrstofftechnik.de

Fiebig-Nährstofftechnik is a producer of high-quality ani-mal serum and animal blood specialties. Its productionprogram comprises sterile, defibrinated and stabilizedblood from sheep, goats, horses, cattle and rabbits for theproduction of blood agars and other biotech applica-tions. Fiebig-Nährstofftechnik has its own farm from whichit obtains its blood and serum products.

Business activities



Further

Applications




37

FluidX Germany

CEO: Ines Schumann

Vogelsangstrasse 12D-61273 WehrheimPhone +49 6081 5836-711Fax +49 6081 [email protected]

We from FluidX are X-perts for long-term storage storageof your bio materials. Already in 1999, we developed ourfirst 2 D coded tubes. Ever since, we have been passion-ate about developing new solutions for storing safely andalso identifying samples. We offer a large variety of sam-ple storage tubes, tracking solutions as well as tube cap-ping and recapping.

Business activities



Further

Applications




Fresenius Kabi AG

CEO: Mats Henriksson

Else-Kröner-Strasse 1D-61352 Bad HomburgPhone +49 6172 686-0Fax +49 6172 [email protected]

Fresenius Kabi is a global healthcare company that spe-cializes in lifesaving medicines and technologies for infu-sion, transfusion and clinical nutrition. The company’sproducts and services are used to help care for criticallyand chronically ill patients. Fresenius Kabi’s product port-folio comprises a comprehensive range of I.V. genericdrugs, infusion therapies and clinical nutrition productsas well as the medical devices for administering theseproducts. Within transfusion technologies, Fresenius Kabioffers products for the whole blood and blood compo-nents collection and processing as well as for transfusionmedicine and cell therapies.

With its corporate philosophy of “caring for life”, the com-pany is committed to putting essential medicines andtechnologies in the hands of people who help patientsand finding the best answers to the challenges they face.

Business activities



Further

Applications




38

Fuchs Patentanwälte Partnerschaft mbB

Westhafenplatz 1D-60327 Frankfurt am MainPhone +49 69 2400 859-0Fax +49 69 2400 [email protected]

FUCHS is one of the leading intellectual property law firmsin life sciences and chemistry in the Rhein-Main area. Ourservices cover the entire spectrum of intellectual property,including patent, trademark and design law. FUCHS’patent attorneys have both wide-ranging legal expertiseand profound knowledge in natural science and technol-ogy. The pharmacists, biologists, biochemists andchemists in our team help you build the ideal IP portfoliofor your company. Today, IP protection requires far morethan a national strategy. FUCHS has a strong internationalnetwork of partner law firms assuring the highest level ofquality and flexibility for our clients across the globe.Thereby, we are able to quickly and globally carry out indi-vidual legal protection strategies for you. From individualinventors to major corporations – clients from a widerange of sectors value our experience. Lean, modernstructures enable us to react at the shortest notice anddeliver tailored solutions to meet your own special needs.

Business activities



Further

Applications




GBG Forschungs GmbH

CEO: Prof. Dr. Gunter von Minckwitz

Martin-Behaim-Strasse 12D-63263 Neu-IsenburgPhone +49 6102 7480-0Fax +49 6102 [email protected]

"Healing through innovation, competence and partner-ship" has been the vision of the GBG Research Institutesince its foundation in 2003. It allows us professional handling of clinical trials with the highest quality standards, maximum scientific independence and profes-sional neutrality. The German Breast Group (a coopera-tive-academic study group) and the GBG ForschungsGmbH (a professional research institute), jointly fulfill thehigh legal standards required for the conduct of clinicaltrials specialized in breast cancer. In work groups (sub-boards), we develop innovative ideas for new academi-cally oriented trial concepts and monitor the safety of trial participants. Our network consists of approximately500 study sites and 1000 clinical investigators. We alsocooperate with both national and international studygroups as well as pharmaceutical companies to ensurethe success of our trials.

Business activities



Further

Applications




39

Genius GmbH

CEO: Prof. Dr. Kristina Sinemus

Robert Bosch Straße 7D-64293 DarmstadtPhone +49 6151 6272-300Fax +49 6151 [email protected]

Mediating between the worlds of science and society – thisis our task. We see our role primarily as a builder of bridges,illuminating the complex interrelations of the life sciencesfor specific target groups. Our integrated communicationstrategies combine public relations, public affairs, internetand traditional media, strategy and dialogue processes,media training, scientific studies, event management, mod-eration and mediation. We are supporting clients in theindustrial, service and public sectors with strategy advice,studies, press and public relations, editing, mediation, etc.Our interdisciplinary team combines scientific know-howwith practice-orientated expertise. Natural scientists withlong-term experience form the core and experts with spe-cial background or long-established practice and experi-ence in journalism, communication and advertising roundthe team off. A special focus of the professional work is onnutrition, energy, environment, biotechnology, renewableraw materials and biofuels, health issues and agribusiness.

Business activities



Further

Applications




GenXPro GmbH

CEO: Dr. Peter Winter

Altenhöferallee 3D-60438 Frankfurt am MainPhone +49 69 9573-9710Fax +49 69 [email protected]

GenXPro GmbH is well-recognized worldwide for its innovative genome-based solutions for all sectors of the life sciences. These provide to customersas well as to the company itself hitherto unachievable insights into complexprocesses of life which determine health and disease, productivity and per-sonal fate. Since its foundation in 2005, GenXPro has become a well-respected service provider and partner in public and commercial projects.Our technologies address all phases of the expression of genomes. In humanresearch, we contribute substantially to diagnosis and prevention of diseasesand development of new drug targets. In agriculture, we assist in acceleratingplant and animal improvement at significantly reduced costs. We developtoxicological tests that help to substantially reducing the number of animalsneeded to assess the safety of products. Recently, the decoding of genomesby Next-Generation-Sequencing gained unprecedented precision. GenXProdeveloped established and automated standard preparations for all types of samples from human, plant and animal tissues and from body fluids.Sequencing of these samples generates large amounts of data that areturned into knowledge by GenXPro’s bioinformatics unit. GenXPro’s cancerresearch identified novel biomarkers and therapeutic targets and enablesindividualized diagnosis and prognosis of cancers and other diseases.

Business activities



Further

Applications




40

Genzyme GmbH – a Sanofi company

CEO: Martina Ochel

Siemensstrasse 5BD-63263 Neu-IsenburgPhone +49 6102 3674-0Fax +49 6102 [email protected]

Genzyme is committed to discovering and deliveringtransformative therapies for patients with rare and specialunmet medical needs, providing hope where there wasnone before.

Genzyme has pioneered the development and deliveryof transformative therapies for over 30 years. Founded in1981 in Boston, Massachusetts, Genzyme evolved from atiny start-up with just a handful of employees to one ofthe world’s leading biotech companies. Acquired bySanofi in 2011, Genzyme now benefits from the reach andresources of one of the world’s largest pharmaceuticalcompanies, with a shared commitment to improving thelives of patients.

Business activities



Further

Applications




GFE Blut GmbH

CEO: Prof.Dr. Kurt W. Roth


Specialized in viral nucleic acids detection (DNA andRNA) by Real-Time PCR in the framework of blood dona-tion testing, the products of GFE Blut mbH comply withthe highest quality standards (CE-Certification accordingto IVDD guidelines) and therefore open up a multitudeof possibilities for handling molecular biological samples.The reagents can either be used manually or fully auto-mated, depending on what is best suited to meet cus-tomer specifications.

Additionally, GFE Blut’s constantly growing portfolio alsospans the complete range from manual over semi-auto-mated to fully automated sample processing solutions forthese assays. As one of the latest developments GFE Blutis providing to their customers as the first company in theworld a HIV-1 Triple Target Test to make blood testingmore safer.

Business activities



Further

Applications




41

Patentanwälte Gierlich&PischitzisPartnerschaftsgesellschaft

CEOs: Dr. Dipl.-Biol. Anastassios Pischitzis Dr. Dipl.-Chem. Johannes Gierlich

Gerbermühlstrasse 11D-60594 Frankfurt am MainPhone +49 69 6032 945-0Fax +49 69 6032 [email protected]

This firm of patent attorneys in Frankfurt am Main pro-vides legal advice on technical aspects of trademark andpatent protection for universities, research institutes anda wide range of small and mid-sized enterprises in Ger-many and abroad. In view of the background with itspatent attorneys (biology, biochemistry and chemistry)and their extensive experience of providing advice onbiotechnology issues, Gierlich & Pischitzis is familiar withall areas of the field, including highly specialized ques-tions.

Gierlich & Pischitzis is a full-service firm dedicated to pro-viding clients with the best possible legal advice and pro-tection for their innovations. Its services cover advice onapplying for, defending and enforcing patents, trade-marks, utility models and designs. The firm also providesfreedom-to-operate opinions on new products and duediligence opinions for the evaluation or transfer of rights.

Business activities



Further

Applications




GOBIO GmbH

Scheidertalstrasse 63 aD-65326 AarbergenPhone +49 6120 926434Fax +49 6120 [email protected]

GOBIO stands for competence and experience in eco-toxicology and applied Biology. Our work focuses onecotoxicological test procedures according to DIN / ENISO 17025, the development of test systems for thedetection of endocrine disruptors, chemicals testing,implementation of the EU Water Framework Directiveand qualified sampling of various environmental com-partments.

Business activities



Further

Applications




42

Hilgenberg GmbH

CEO: Ingo Hilgenberg

Strauchgraben 2D-34323 MalsfeldPhone +49 5661 730-30Fax +49 5661 [email protected]

With almost 100 years of experience, Hilgenberg GmbHis a producer of high-precision glass products for differ-ent industries. You find our products in practical terms inlaboratories as well as in other products, where we areable to play off one of our strengths: customized devel-opment and manufacture of the products and prototypesaccording to our customers needs.

We supply more than 3.000 customers worldwide withe.g. capillaries, test tubes, pipettes as well as glass beadsfor different fields of application.

Business activities



Further

Applications




humatrix AG

CEO: Dr. Anna C. Eichhorn

Reissstrasse 1aD-64319 PfungstadtPhone +49 6151 60159-0Fax +49 6151 [email protected]

humatrix AG is a biotechnology company specialized inthe analysis of human DNA. In the field of private pater-nity testing humatrix has set quality standards. Mean-while, the company’s focus is in the area of personalizedmedicine.

In that field, humatrix offers nationwide in collaborationwith physicians and pharmacies DNA-based test systemsto avoid inefficiencies and adverse reactions in drug ther-apies and preventive DNA diagnostics to improve thequality of life.

Business activities



Further

Applications




43

Hycor Europe Bio Crest B.V. (Niederlassung Deutschland)

CEO: Richard Aderman

Waldauer Weg 84D-34253 LohfeldenPhone +49 561 816 7000-0Fax +49 561 816 [email protected]

HYCOR is a manufacturer and supplier of high-qualitydiagnostic instrumentation and in-vitro diagnostics forallergy and autoimmune testing. Since its founding,HYCOR has expanded its presence into allergy andautoimmune products used in clinical laboratories, hos-pitals and doctors’ offices worldwide.

Among its products, HYCOR markets the HYTEC® andAUTOSTAT™ brands. The company is focused on deliv-ering products that provide the highest value to cliniciansthrough innovation, reliability and customer service. TheHYTEC288 offers a broad allergy and autoimmunemenue optimized on a single platform. Hycor’s mission isto drive new products, technologies and medical educa-tion materials designed to improve patient care andadvance healthcare globally.

Business activities



Further

Applications




IBACON GmbH

CEO: Dr. Ralf Petto

Arheilger Weg 17D-64380 RossdorfPhone +49 6154 697-0Fax +49 6154 [email protected]

Founded in 1994, IBACON is an independent contractresearch institute serving the global chemical and phar-maceutical industry. IBACON currently has around 130employees, mainly scientists and technical staff. The test-ing facility is certified as conforming to Good LaboratoryPractice (GLP) standards and offers a wide range ofaquatic and terrestrial ecotoxicology studies (laboratoryand field tests), physical and chemical parameters andenvironmental fate analyses.

All studies are performed in accordance with internation-ally valid guidelines (e.g. OECD) for the registration andapproval of plant protection products, industrial chemi-cals, biocides, and products for human and veterinarymedicine. IBACON is offering standardised test series aswell as tailor-made study designs. In addition, IBACONregularly takes part in ring tests to establish new testingprocedures and guidelines.

Business activities



Further

Applications




44

ID-Labor GmbH

Peter-Sander-Strasse 43 cD-55252 Mainz-KastelPhone +49 6134 601 9150Fax +49 6134 601 [email protected]

ID-Labor GmbH, founded as I.D. Labor für DNA-Analysein 1998, is a company which is specialized on DNA profil-ing and parental testing.

Business activities



Further

Applications




Immundiagnostik AG


Stubenwald-Allee 8aD-64625 BensheimPhone +49 6251 70190-0Fax +49 6251 [email protected]

Immundiagnostik AG is an internationally active diagnos-tics company that develops and produces innovativeimmunoassays and other analytical methods for routineclinical and life science research. The product portfolio iscompleted by a broad range of antibodies and antigens.

The company focuses on providing effective tools for pre-vention, differential diagnosis and therapy monitoring inthe areas of gastroenterology, cardiovascular diseases,disorders of the skeletal system and oxidative stress.Cooperations with the pharmaceutical industry and atight scientific network provide the basis for successfulproduct development.

Business activities



Further

Applications




45

Immunolab GmbH

CEO: Dr. med. Viktor Růžička

Otto-Hahn-Strasse 16D-34123 KasselPhone +49 5614 91742-0Fax +49 5614 [email protected]

Immunolab GmbH develops and manufactures ELISA kits for clinical diag-nostics and for food analytics. Immunolab was founded in 1992, is certifiedaccording to ISO 9001 / ISO 13485 and cooperates with numerous com-panies worldwide. Recently, Immunolab extended its international involve-ment by joining the Biovendor Group. In addition to offering its portfolioof validated products, Immunolab always attempts to implement individ-ually adapted test kits requested by customers.

Most products focus on clinical diagnostics by detecting human antibodies(IgG, IgA, IgM) against bacteria, parasites and viruses that cause differenthuman infectious diseases including mumps, measles, whooping cough,borreliosis and many others. Furthermore, Immunolab offers products fordiagnostics of allergy and food intolerance (IgE, IgG and IgG4).

Another set of Immunolab products are immunological test kits for meas-uring concentrations of contaminants and additives in food and beverageslike milk, meat, nuts or fruit juice. Testable substances are mycotoxins,antibiotics and vitamins, but also other foodstuffs like peanut and gluten,which may result in severe allergic reactions of some humans.

Business activities



Further

Applications




INTEGRA Biosciences GmbH

CEO: Uwe Schäfer

Ruhberg 4D-35463 FernwaldPhone +49 6404 809-0Fax +49 6404 [email protected]

For more than 40 years, INTERA Biosciences GmbH has been your compe-tent partner for laboratory equipment and devices. Today, we see ourselveseven more as provider of high-quality laboratory equipment and of servicesin the field of products, technology and user consulting. It is our commonaim to provide efficient solutions that enable our clients to work in a long-term, reliable and cost-effective manner.

Today, our own development and production is complemented by high-quality and innovative brands – like INTEGRA Biosciences, FedegariAutoklaven AG, NuAire Inc, Micronic B.V. and some others that are marketedexclusively. For many years, we have been business partners of these worldleading producers of small laboratory devices, industrial laboratory equip-ment and other scientific laboratories. Right from the beginning, our out-standing service has been the advisory competence of all our staff. Withour qualified customer services operators, rapid reaction time and reliableservice, we can support you in all your questions and technical needs. Ofcourse, IQ, OQ, PQ or GMP, GLP, CE, ISO and TÜV as well as NSF und FDA,but also DIN EN, etc., can be met in reference to customers‘ orders.

Business activities



Further

Applications




46

Intermed GmbHInstitut für medizinische Forschung und Arzneimittelsicherheit

CEO: Dr. Marco von Behren

Bahnhofstrasse 36D-65185 WiesbadenPhone +49 611 90059-0Fax +49 611 [email protected]

Intermed is commissioned under the German MedicinesAct to conduct studies on how to improve the efficacyand tolerability of medicines. It works on the develop-ment of modern medication in collaboration with leadingpharmaceutical companies. The efficacy of the sub-stances has already been proven in preliminary studiesand the aim is to enhance their effectiveness and reduceside-effects.

Intermed specializes, among other things, in psychiatricdiseases, arterial hypertension, metabolic and hormonaldisorders, pain related and respiratory related diseases.It conducts Phase II-IV studies at its sites in Wiesbadenand Frankfurt am Main.

Business activities



Further

Applications




JUMO GmbH & Co. KG

CEOs: Dipl.-Ing. Bernhard Juchheim, Dipl.-Kfm. Michael Juchheim

Moritz-Juchheim-Strasse 1D-36039 FuldaPhone +49 6616 003-0Fax +49 6616 [email protected]

JUMO is a family-owned enterprise in the third genera-tion. Its product spectrum covers components and sys-tem solutions for the measurement, control, recordingand analysis of physical and chemical parameters. Theproducts range from sensors for temperature, pressureand analytical measurement to the control and recordingof measurement data. These instruments and systems areused in the pharmaceutical and biotechnology industry.

Thanks to its two prefabrication divisions for metalwork-ing and electronic modules, the company can provide afast, flexible response. A global service network, consist-ing of 24 independent subsidiaries abroad and addi-tional external service partners, ensures that JUMO isalways close to its customers.

Business activities



Further

Applications




47

Keller Medical GmbH

CEO: Dipl.-Ing. Karl-Heinz Keller

Wiesbadener Weg 2aD-65812 Bad Soden/Ts.Phone +49 6196 56163-0Fax +49 6196 [email protected]

We read the blood – Keller Medical is a distributor ofinnovative Point-of-Care-Diagnostic with single-usereagents and almost maintenance-free analysers. Whileour focus is on POCT coagulation, we also offer instru-ments, tests and quality control material for blood gases,oximetry, platelet function tests and others. We market,sell and service our analysers and train and educateusers.

Our second product range is transcutaneous monitors forblood gases (pCO2 and pO2) and NIRS for use in neona-tology, pneumology, intensive care and cardiac surgery.Our mission is to offer our customers flexible solutionswith innovative products and an excellent service. KellerMedical is a competent partner for hospitals and manu-facturers.

Business activities



Further

Applications




KEPOS GmbH

CEO: Barbara Hoffbauer

Altenhöferallee 3D-60438 Frankfurt am MainPhone +49 69 9573 [email protected]

KEPOS considers itself as partner for life science institu-tions as far as preparing scientists for alternative careerpaths is concerned. KEPOS is well versed with scientists,speaks their language and at the same time is expert for the employers. KEPOS employees and counselorsconsider themselves as bridge-builders. It is a matter ofimmediate concern for them to bring people together.

As professional networker KEPOS seeks constantexchange with human resources managers in the field ofacademic research as well as with business representa-tives and non-profit enterprises and open these contactsfor its clients. Enabling rather than counseling is theobjective of the daily work that KEPOS’s clients can ben-efit from. Experience and knowledge in connection withempathy and communication skills in different contextsmake KEPOS fit to work in this field of development.

Business activities



Further

Applications




48

Otto E. Kobe KG

CEO: Otto-Alexander Kobe

Anneliese Pohl Allee 5D-35037 MarburgPhone +49 6421 68507-0Fax +49 6421 [email protected]

Kobe is a medium-sized company that offers products oflaboratories, cleanroom and production. We only offerhigh-quality products of well-known producers as well asour private label LLG-Labware. These products are beingused in biotechnology, the pharmaceutical industry, med-ical technology, research and development.

Our qualified staff provides expert knowledge in all appli-cation-related matters. Service, individuality and compe-tence are the core values of our company. Due to strongpartners and our central distribution, we can guaranteethe complete supply of your laboratory. Our servicesspectrum contains more than 700.000 products, like la-boratory chemicals, consumables, devices and laboratoryfurniture. As a special service, we also offer custom-madedevices, repair services, pipette calibration and cartridgeregeneration.

Business activities



Further

Applications




LI-COR Biosciences GmbH

CEO: Glen McMurdo

Siemensstrasse 25 aD-61352 Bad HomburgPhone +49 6172 1717-771Fax +49 6172 [email protected]/bio

LI-COR Bioscience GmbH is a subsidiary of the US com-pany LI-COR Bioscience, a producer of innovative sys-tems for biotechnological research. It specializes in thedevelopment of sensitive labeling and detection systemsbased on infrared technology. These are used for a widerange of applications in proteomics and enomics.

Its Germany subsidiary Li-COR Biotechnology is respon-sible for product distribution and support in Germany,Austria and Switzerland.

Business activities



Further

Applications




49

LOT-QuantumDesign GmbH

CEO: Ralph Köhler

Im Tiefen See 58D-64293 DarmstadtPhone +49 8806-0Fax +49 [email protected]

LOT-QuantunDesign in Darmstadt is the European head-quarters and main office of the LOT-QuantumDesigngroup which is one of the most powerful European sup-pliers of components and leading-edge instrumentationwith applications in materials characterization, thin filmanalysis, special cameras and imaging, spectroscopy,photonics and nano- and biotechnology.

A dedicated team of more than 100 people in most Euro-pean countries is supported by state of the art infrastruc-ture in order to provide fast, flexible and reliable serviceto customers. The company provides leads, workingadvice, and individual solutions for its customers’ appli-cations. It can also carry out tests and sample measure-ments in its application lab.

Business activities



Further

Applications




Matrix BioScience GmbH

CEO: Gerhard Quelle

Industriestrasse 40-42D-69509 MörlenbachPhone +49 6209 794-784Fax +49 6209 [email protected]

MATRIX BioScience GmbH combines 40 years of experi-ence in the field of biochemical research with applicationof its results in the field of medicine and related areas, aswell as in product development and production. Withdecades of research on extracellular matrix, collagen andcell culture, our expertise will help you to reach yourgoals.

We have the know-how for production of highly purifiedinjectable sterile collagen implants. Our wide-rangedportfolio includes connective tissue components and col-lagen types for cell culture and analytics. We are highlyexperienced in cosmetic anti-aging active ingredients,asceptic filtration, contract research, radical scavengingefficacy tests. We continually expand our product andservice portfolio according to customer needs.

Business activities



Further

Applications




50

MedSurv GmbH

CEO: Mattes Hamann

Friedrich-Ebert-Strasse 1D-61130 NidderauPhone +49 6187 90591-40Fax +49 6187 [email protected]

MedSurv GmbH is a spin-off of Hamann Softwareentwick-lung and a vendor of a web-based eCRF solution for thedocumentation of clinical trials that is fully compliant to21 CFR/Part 11. Experience obtained in clinical trials dat-ing back to the year 2000 has led to the development ofa tool that improves quality of data, reduces workload,increases efficiency and delivers a major cost reductionfor data acquisition.

Validated data is stored in a database system and hostedat a high-security data center in Germany. The toolencompasses all processes of relevance to trials, such asonline monitoring, audit trails, SAE management, ran-domization and many more. The system is used by thepharmaceutical industry, research centers and CROs. Themodular “pay per use” service is highly attractive for cost-conscious organizations that want to avoid high pre-investment costs for systems and software.

Business activities



Further

Applications




Merck KGaA

CEO: Dr. Karl-Ludwig Kley

Frankfurter Strasse 250D-64293 DarmstadtPhone +49 6151 72-0Fax +49 6151 [email protected]

Merck is a leading company for innovative and top-qual-ity high-tech products in the pharmaceutical and chemi-cal sectors. With its four divisions Merck Serono, Con-sumer Health, Performance Materials and Merck Milli-pore, Merck generated total revenues of € 11.1 billion in2013. The portfolio of Merck Millipore comprises prod-ucts for life science research such as assays, analyticalreagents, test kits, products and services for the entireprocess chain in the pharmaceutical and biotech industry.

Merck is the world’s oldest pharmaceutical and chemicalcompany – since 1668. Merck, Darmstadt, Germany isholding the global rights to the Merck name and brand;exceptions are Canada and the United States, where thecompany is known as EMD.

Business activities



Further

Applications




51

Mettler-Toledo GmbH

Ockerweg 3D-35396 GießenPhone +49 641 5070Fax +49 641 [email protected]

Mettler Toledo is a leading global manufacturer of preci-sion instruments. It is the world’s largest manufacturerand marketer of weighing instruments for use in labora-tory, industrial and food retailing applications.

The company also holds top-three market positions inseveral related analytical instruments and is a leadingprovider of automated chemistry systems used in drugand chemical compound discovery and development. Inaddition, Mettler Toledo is the world’s largest manufac-turer and marketer of metal detection systems used inproduction and packaging.

Business activities



Further

Applications




Milenia Biotec GmbH

CEO: Dr. Ralf Dostatni

Versailler Strasse 1D-35394 GießenPhone +49 6419 48883-0Fax +49 6419 [email protected]

Milenia Biotec GmbH develops, produces and marketsimmunodiagnostics globally. The company was foundedin 2000 as a spring-off of DPC Biermann GmbH in BadNauheim. Its core products are “Point-of-Care”-tests forthe diagnosis of allergies, infections and for the measure-ment of immune mediators. Product marketing is carriedout by qualified sales representatives in Germany, and inother countries by independent distributors.

Business activities



Further

Applications




52

MK Versuchsanlagen GmbH

Stueckweg 10D-35325 Mücke-MerlauPhone +49 6400 95760-30Fax +49 6400 [email protected]

MK constructs and manufactures laboratory systems, made of modern plas-tics or other material, for the use in technical colleges (FH, TH) and univer-sities as well as in private research institutes and industrial testing plants.Our philosophy, to provide problem-oriented solutions to the customer, isachieved by planning, constructing and manufacturing all testing plantsin close cooperation with our customers. We provide you with expert sup-port and give professional advice on how to solve your specific problems.Our testing plants are reliable and due to their user-related constructioneasy to use in daily handling.

Worldwide, research institutes and industrial companies in the field of cli-mate research, geology, mineralogy, planetology, volcanology and forreconnaissance of mineral resources and rating of workability, are rankedamong our main customers. Additionally, our plants will be found in thefield of medical ultra-trace analytics. Furthermore, we number manufac-turers of filling plants and of isolators among our customers, as well as thepharmaceutical industry as end customer. According to our product lead-ership, we reckon the worldwide leading pharmaceutical companiesamong our customers.

Business activities



Further

Applications




MORPHISTO GmbHEvolutionsforschung und Anwendung

CEO: Dr. Michael Gudo

Weismüllerstrasse 45D-60314 Frankfurt am MainPhone +49 69 400 3019-60Fax +49 69 400 [email protected]

Histology, immunohistochemistry, cytology and hematology: Being the firstspin-off of the Senckenberg Research Institue, MORPHISTO offers a wide rangeof laboratory and research services and special products for the daily routinein medical and biological laboratories. We are involved in product develop-ment, clinical studies and contract research for our partners in the pharmaindustry or at universities. We are your partner for all kinds of research projectsconcerning histology, cytology, immunohistochemistry, comparative anatomyor evolutionary biology. Profit from our experience in research, applicationand method development in paraffine histology, cryo-sectioning and immunestainings. With our laboratory equipment, we are able to section all kinds oftissues or other materials, starting from small biopsies up to whole body sec-tions of rats for autoradiography. Our unique selling point is the combinationof the service lab with a production lab for laboratory chemicals. We produceready-to-use chemicals for histology, cytology and hematology and we usethese stains and dyes ourselves in our lab. Our products are double tested:first by our quality management and second by our service lab under real lifeconditions. Finally, we offer trainings in various methods of histology, cytologyand immunhistochemistry in our lab, as well as in-house for our customers.

Business activities



Further

Applications




53

MOTUS Engineering GmbH & Co. KG

CEO: Dipl.-Ing. Alexander Wagner

Am Wall 17D-35041 MarburgPhone +49 6420 8382-50Fax +49 6420 [email protected]

MOTUS is a manufacturer of machinery and special instal-lations. We are specialized in consulting, engineering,technical development, qualification-activities, RAB-sys-tems, containments, automatic Charging systems forfreeze dryers, powder transfer systems, magnetic stirrersand special machines for the Life-Sciences- and pharma-ceutical industry.

a Engineeringa Machinesa Equipmenta Accessoriesa Optimisation of production lines

Business activities



Further

Applications




mti diagnostics GmbH

CEO: Alexandra Eiden

Limburger Strasse 45D-65510 IdsteinPhone +49 6126 9595-262Fax +49 6126 [email protected]

mti diagnostics GmbH was established to meet the grow-ing need for a diagnostics company offering a wide rangeof high-quality diagnostic products and OEM manufac-turing. With their experience in developing and manufac-turing diagnostic products and their use in clinical labor-atory setting, mti diagnostics offer their expertise to helptheir customers to provide the best and most cost-effec-tive products.

The company is widely recognized for in-depth knowl-edge of manufacturing biochemistry kits, immunoturbidi-metric tests and auxiliary solutions such as system clean-ers, extensive contract manufacturing capabilities, largelot production capacity, extremely high-quality and pro-ductivity, CE-registered and IVD MD-compliant manufac-turing facilities. As a supplier of in-house products and adistributor of third party products, the company can cus-tomize products for specific applications, enabling it tooffer a broad product line.

Business activities



Further

Applications




54

Mundipharma GmbH

CEO: Gunther Niederheide

Mundipharmastrasse 2D-65549 LimburgPhone +49 6431 7010Fax +49 6431 [email protected]

After having been founded in 1967, Mundipharma hasspecialised in analgesics. Further areas of competenceare oncology and respiratory diseases. Mundipharma isvery service-oriented and develops highly effective phar-maceuticals with the best possible tolerability, thus opti-mizing the therapy for both physicians and patients.

In Germany, this medium-sized company belongs to theleading drug manufacturers. Mundipharma has 980 staffmembers in Germany, 100 of which are employed at thecompany research center in Limburg. It is Mundipharma’sobjective to provide long-term support for patients byoffering highly effective medication.

Business activities



Further

Applications




N-Zyme BioTec GmbH

CEO: Dr. Stefan Marx

Haasstrasse 9D-64293 DarmstadtPhone +49 6151 39127-0Fax +49 6151 [email protected]

N-Zyme BioTec is a science driven company founded in1999 as a spin-off of two universities in Darmstadt. Inrecent years and based on the previously developedtechnologies, three different business activities (pharma/diagnostic, beverage biotechnology and sustainableleather tanning) were joined with industrial partners andreleased as independent entities. After a restructuringprocess in 2012, the company now is specializing underthe claim „unlocking the potential of nature” in research,development, production and marketing of bioactivesfrom natural produce in the application fields food/pet-food, cosmetic, pharma and chemical industries. Basedon our AMBOSS technology platform, different activemolecules from olive side streams are generated, modi-fied and functionalized according to the application spe-cific requirements. Besides the AMBOSS unit, N-ZymeBioTec is providing biochemical and analytical serviceactivities to different life science industries.

Business activities



Further

Applications




55

nadicom GmbH

CEO: Dr. Bernhard Nüßlein

Pflanzgarten 10D-35043 MarburgPhone +49 6421 13175Fax +49 7216 [email protected]

nadicom specializes in GMP-compliant identification anddifferentiation of bacteria, fungi and yeasts in pure cul-tures, environmental samples and complex mixed cul-tures. Close cooperation with the Max Planck Institute inMarburg and the Institute for Applied Microbiology ofKarlsruhe Institute of Technology guarantees and facili-tates knowledge transfer from basic to applied research.

The company’s services are focused on molecular-biolog-ical identification and differentiation of microorganisms,DNA fingerprints, contract research and consultancy.nadicom optimizes its methods through its own researchand constant further development, and ensures theirpractical feasibility by putting them regularly into prac-tice.

Business activities



Further

Applications




NeuroCode AG

CEO: Ingrid K. Keplinger-Dimpfel

Sportparkstrasse 9D-35578 WetzlarPhone +49 6441 2002-030Fax +49 6441 [email protected]

NeuroCode AG is a certified contract research organiza-tion specialized in brain research. Preclinical and clinicallabs allow testing of pharmaceuticals and nutraceuticalsacting on the brain. Based on neurophysiological meth-ods like field potentials and EEG recordings which havebeen developed by NeuroCode itself, are used in drugdiscovery and translational medicine. One of the maintopics is cognitive research where a combination of quan-titative EEG recording (Neurocode Tracking) and eyetracking is used to recognize individual responses toaudio-visual stimuli like images or videos. This combina-tion is also used in marketing and advertisement researchwhere about three images per second from the brainreflect cognitive and emotional reactions. Spectral signa-tures of electric brain activity also known as “Enkephalo-glyphs” serve to gather more information of the brainscommunication structure than any other method andhave been called mirror of the psyche.

Business activities



Further

Applications




56

New England Biolabs GmbH

Brüningstrasse 50, Geb. B852D-65926 Frankfurt am MainPhone +49 69 305-23140Fax +49 69 [email protected]

New England Biolabs (HQ based in Ipswich, U.S.) is a rec-ognized world leader in the discovery, development andcommercialization of recombinant and native enzymesfor genomic research. For nearly four decades, NEB hasbeen shaping the landscape of bioscience research bydiscovering, developing and supporting superiorresearch reagents for the field of molecular biology incl.restriction enzymes, PCR Polymerases as well as reagentsfor Next-Gen-Sequencing. New England Biolabs GmbHis the NEB service and logistics hub for customers in Ger-many, Austria and Eastern Europe. NEB is also the exclu-sive source for reagents from Cell Signaling Technology(CST) in Germany and Austria. Founded by scientists fromNEB, CST has become a world leader in the productionof the highest quality antibodies utilized to expandknowledge of cell signaling pathways underlying severaldiseases including cancer, Alzheimer and Parkinson.

Business activities



Further

Applications




onoff engineering GmbH

CEO: Rolf Arneke

Niels-Bohr-Strasse 6D-31515 WunstorfPhone +49 5031 9686-0Fax +49 5131 9686-96www.onoff-group.de

a Solution Partner for Process Automation in chemicals,pharmaceutical, food & beverage, water technologyand oil & gas industry.

a IT-Solution in areas of MES application in processindustry.

a Installation services, manufacturing of control cabinets, Field services, Life cycl services.

a Consulting in IT-Networks and security as well as IT-Infrastructure and services.

a Consulting in Automation architecture design inprocess industry.

Business activities



Further

Applications




57

PAREXEL International GmbH

CEO: Josef H. von Rickenbach

Waldecker Strasse 10-12D-64546 MörfeldenPhone +49 6105 9430-0Fax +49 6105 9430-502www.parexel.com

PAREXEL International Corporation is a leading globalbiopharmaceutical service organization and a premierpartner for clients who rely on the company’s expertiseand flexibility to achieve their goals. Companies of allsizes can leverage PAREXEL’s global resources, world-wide infrastructure and experience to improve early-stage decisions, reduce development timelines and max-imize investments to increase efficiency, quality, andsafety.

The company’s offerings include regulatory expertise,Phase I-IV clinical research services, eClinical technolo-gies to accelerate development and integrated commer-cialization services. Headquartered near Boston, Massa-chusetts, PAREXEL operates in 75 locations in 50 coun-tries around the world.

Business activities



Further

Applications




PKCie GbR – Prof. Köpper & CieManagement Consultants

CEO: Prof. Dr. Sabine Köpper

Eschersheimer Landstrasse 44D-60322 Frankfurt am MainPhone +49 69 505 097-50Fax +49 69 505 097-579www.pkcie.com

PKCie specializes in executive searches and managementconsulting for life science companies and other scientificinnovators at all stages of development. PKCie’s interdis-ciplinary team consists of experts with many years ofexperience and insider know-how from science, industryand consulting – something we consider essential fordelivering top quality results in a highly specialized field.

We search and find the right candidate for senior man-agement, executive and non-executive boards. PKCieestablished an outstanding reputation in the marketsthanks to their stringent quality standards.

Business activities



Further

Applications




58

Polygen GmbH

Karlstrasse10D-63225 LangenPhone +49 6103 55-559Fax +49 6103 [email protected]

PolyGen GmbH is an internationally renowned supplierof DNA synthesizers for biomedical sciences. Since 1990,PolyGen has been developing, manufacturing and mar-keting DNA synthesizers for the production of Oligonu-cleotides. PolyGen distributes its products and servicesin Germany through sales and marketing directly and viaselected specialized dealers worldwide.

Due to intensive product development, Oligonucleotidesare successfully being synthesized throughout the worldwith PolyGen synthesizers.

In intensive cooperation with universities and researchinstitutions, PolyGen’s product range is constantly beingoptimized. This dialogue with other institutions helps usto define our goals and leads to product expansion.

Business activities



Further

Applications




PPH plus GmbH & Co. KG

CEO: Dr. med. Johanna Schenk


Operational and consultancy services in clinical development programs topharma, medical device and biotech companies from all over the world(trials from phase I to IV). We provide clinical trial project leadership fromearly planning and set-up to study report writing including selection ofoperational service providers. In addition, we offer “medical monitoring”and support with pharmacovigilance obligations as well as managementconsultancy in strategic outsourcing and operational benchmarking.

Core competencies:a National / international project management services to pharma,

medical device and biotech companiesa Study start-up services utilizing the ViS Research platforma Medical leadership for clinical studiesa Pharmacovigilance servicesa Management consultancy in strategic outsourcing and operational

benchmarking in clinical developmenta Medical Science Liaisona Qualified selection of solution providers

Business activities



Further

Applications




59

Premier Research Germany Ltd.

Europaplatz 5D-64293 DarmstadtPhone +49 6151 8280-0Fax +49 6151 8280-110www.premier-research.com

Premier Research is a global solutions-driven CRO whichcombines a therapeutic focus with operational expertiseto deliver clinical trial services for biopharmaceutical andmedical device companies.

It focuses on clinical research into analgesia, neuro-science, oncology and cardiovascular disease and hasexperience in medical device and cardiovascular diseaseand has experience in medical device and pediatric clin-ical research.

Business activities



Further

Applications




Preventis GmbH


Wiesenstrasse 4D-64625 BensheimPhone +49 6251 70711-0Fax +49 6251 [email protected]

Preventis GmbH, founded in 2003, is a globally operatingdiagnostics company focusing on the early prevention ofdiseases. The company’s rapid tests are modern diagnos-tic tools that represent the latest scientific standard andcover most areas of preventive medicine as well as infec-tiology and reproductive health.

The diagnostic kits are reliable, easy to use and deliverresults in just a few minutes. They are therefore ideal forpoint-of-care diagnostics at the physician’s practice, in aclinical setting or even at home. Preventis’ special focusis the development of innovative tests for the early detec-tion of colorectal cancer. In particular, the Bensheim-based company has established nation-wide corporatescreening programs for colon cancer.

Business activities



Further

Applications




60

Prolytic GmbH

CEO: Dr. Dorothee Krone

Alt Fechenheim 34D-60386 Frankfurt am MainPhone +49 69 4109 2534Fax +49 69 4269 [email protected]

Prolytic GmbH is a GLP-certified contract laboratory spe-cialized in bioanalytics and pharmacokinetics as well ascomplex analytical questions.

We develop and validate methods (e.g. HPLC, LC-MS/MS,RIA, ELISA), analyze biological samples of preclinical andclinical studies as well as samples with complex compo-nents, and carry out both their compartmental and non-compartmental pharmacokinetic evaluation.

Due to our long-standing experience in bioanalytics andpharmacokinetics, we are able to give expert advice toour clients.

Our highly qualified employees and our modern equip-ment make it possible to work rapidly and professionallyon the most complex assignments.

Business activities



Further

Applications




Provadis School of InternationalManagement & Technology AG

CEO: Prof. Dr. Udo Müller-Nehler

Industriepark Höchst, Geb. B845D-65926 Frankfurt am [email protected]

The Provadis School of International Management andTechnology AG (short name: Provadis Hochschule) wasfounded in 2003 as a nationally accredited university ofapplied sciences.

The Provadis Hochschule offers a bachelor study programfor candidates seeking an academic carreer parallel to afull time job in biotechnology and pharmaceutical com-panies. The course Biopharmaceutical Science focuses onresearch and developement of large molecule drugs andtheir production using microbes or cell cultures. In addi-tion to the scientific contents, the course also offers indus-try related contents like aspects of controlling and scien-tific communication.

Business activities



Further

Applications




61

PURIMEX

Auf dem Wildhagen 8D-34393 GrebensteinPhone +49 5674 921 092www.purimex.com

Synthesis of high quality DNA/RNA-oligonucleotides spe-cialized on DNA oligos up to 150 bases, RNA oligonu-cleotides up to 100 bases, complex modified oligos, anti-sense phosphorothioates and dye labelled probes.

Business activities



Further

Applications




Quintiles GmbH

CEO: Tom Pike

Hugenottenallee 167D-63263 Neu-IsenburgPhone +49 6102 296-0Fax +49 6102 [email protected]

For 30 years, Quintiles has been offering solutions for thehealthcare sector and most prominently for the pharma-ceutical industry: clinical research (monitoring and sitemanagement), commercial solutions (until 2010 underthe name of Innovex) and consulting services on the high-est level. The management of the Quintiles subsidiariesin Germany possesses many years of experience in theareas mentioned; the subsidiaries themselves havealways been among the market leaders in Germany.

With far more than 1.000 employees in Germany, westand ready for your challenges. Key services in Germany:clinical monitoring and site management, commercialsolutions, consulting and market access.

Business activities



Further

Applications




62

R-Biopharm AG

CEO: Dr. Ralf Dreher

An der neuen Bergstrasse 17D-64297 DarmstadtPhone +49 6151 8102-0Fax +49 6151 [email protected]

R-Biopharm develops products for clinical diagnosticsand food and feed analysis. In the field of clinical diag-nostics, it concentrates on infectiological stool diagnosis,serological diagnosis of infections and allergy diagnos-tics. The clinical product portfolio is rounded out by inno-vative tests for tumor diagnosis and gastroenterology. Inthe field of food and feed analysis, the product rangecomprises immunological, enzymatic and microbiologicaltest kits to verify residues, constituents and microbiolog-ical contaminations. The test kits allow detection of myco-toxins, antibiotics, hormones, genetically modified organ-isms, risk materials, allergens (food) and pathogen germs.In 2013, R-Biopharm extended its services to personal-ized healthcare. In terms of complementary diagnostics,it covers the entire chain of requirements from customassay development and laboratory services via validationand registration and manufacturing all the way to com-mercialization and project management.

Business activities



Further

Applications




RD-RatioDiagnostics GmbH

CEO: Dr. C.Ranjan Bhaduri

Westerbachstrasse 47D-60489 Frankfurt am MainPhone +49 69 7807 4942Fax +49 69 7807 [email protected]

RD-RatioDiagnostics GmbH is a manifacturer of medicaldiagnostics (ELISA-Kits) specialized in infectious diseases.Development, production and marketing all take place atthe same location in Frankfurt. The company is ISO 13485certified. As the company is strongly export-oriented,85 % of turnover are generated internationally.

Business activities



Further

Applications




63

DR. RIETHMÜLLER M/R/S GmbH

CEO: Dr. med. Hilde Riethmüller-Winzen

Mittelweg 27D-60318 Frankfurt am MainPhone +49 69 1302 56-0Fax +49 69 1302 [email protected]

DR. RIETHMÜLLER M/R/S GmbH was founded in 2001 and providesstraight-forward strategies, know-how and services in the development,registration and marketing of medicinal products and medical devices.Each of the company’s experts in pharmaceutical development, pharma-cology, toxicology, and clinical affairs can look back on at least 25 years ofsuccessful and skilled expertise in international drug development. Thequalified team has achieved numerous registrations (EMEA, MRP, DCP, FDA,Japan) of innovative and generic drugs in the shortest possible time aswell as orphan drug designations. The team assists in securing the endur-ing success of the entire product life cycle.

Clients come from the international pharmaceutical industry, biotechnol-ogy and venture capital companies, university clinics and CRO. Experienceexists in numerous benign and malignant indications, including pediatricand elderly patients. Compounds comprise NCEs, proteins, antibodies,biosimilars; solid, liquid, semiliquid dosage forms; local (inhalative,intranasal, dermal) oral, i.v., s.c., i.m. administration; medical devices.

Business activities



Further

Applications




RSC Pharma LTD. & Co. KG

CEO: Dr. Thomas Schmidts

Gleibergring 23D-35396 GießenPhone +49 6413 092-554Fax +49 6413 [email protected]

RSC Pharma is a service provider engaged in the devel-opment of pharmaceutical and cosmetic preparations,membrane technology, pharmaceutical technology andprocess technology. It cooperates with Gießen Universityof Applied Sciences with the aim of translating scientificknowledge into marketable products for medium-sizedpharmaceutical, cosmetics and food companies.

Its services range from developing highly innovative car-rier systems for precise dermal drug targeting throughthe development of suppositories, liquid medication,hydrophilic nail gels, gelatin capsules and tablets, to con-sulting in the areas of pharmaceutical technology, GMPand applications for membrane technology.

Business activities



Further

Applications




64

Sanofi-Aventis Deutschland GmbH

CEO: Christopher A. Viehbacher

Industriepark Höchst, Bld. K 703D-65926 Frankfurt am MainPhone +49 69 305 30167Fax +49 69 305 [email protected]

Sanofi, an integrated global healthcare leader, discovers, develops and dis-tributes therapeutic solutions focused on patients’ needs. Sanofi has corestrengths in the field of healthcare with seven growth platforms: diabetessolutions, human vaccines, innovative drugs, consumer healthcare, emerg-ing markets, animal health and the new Genzyme. Sanofi is listed in Paris(EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi-Aventis Deutschland GmbH is the German subsidiary. There are onlya few health companies here in Germany that research and develop inno-vative pharmaceutical products, and Sanofi is one of them. Primary focusis on diabetes research and age-related diseases. The Frankfurt facility isglobally networked with the Group’s other research locations and is con-stantly sharing results and ideas with universities, research institutionsand biotech companies. R&D in Frankfurt is seamlessly followed by all othersteps in the pharmaceutical value chain: from active agent production todrug manufacturing to shipping and handling. This also makes Frankfurtthe most important integrated production and manufacturing site withinthe Sanofi Group. The facility also develops and produces its own pens,which are used by patients to administer insulin comfortably and reliably.

Business activities



Further

Applications




ScheBo Biotech AG

CEOs: Dr. Ursula Scheefers-Borchel, Dr. Hans Scheefers, Dr. René M. Kröger

Netanyastrasse 3D-35394 GießenPhone +49 6414 996-0Fax +49 6414 [email protected]

ScheBo® Biotech AG is an independent company special-izing in the development, production and distribution ofinnovative diagnostic products. lts target groups are clin-ical and laboratory physicians and physicians in privatepractice using POC rapid tests. ScheBo® Biotech devel-ops and produces ELISA test kits for the diagnosis ofacute pancreatitis and exocrine pancreatic insufficiency,tumor diagnosis and monitoring as well as ELISA test kitsand POC rapid tests for early detection and screening forcolorectal cancer.

ln addition, ScheBo® Biotech AG holds many interna-tional patents in the above mentioned fields and has asolid intellectual property position. The company also hasacademic alliances with several universities and universityhospitals in Europe, the USA, Japan, Israel and Canada.

Business activities



Further

Applications




65

SciNuTec GmbH

CEO: Guenther Sawatzki

Ricarda-Huch-Strasse 13D-5516 MuenzenbergPhone +49 6033 730-20Fax +49 6033 730-24

SciNuTec GmbH was founded in 1999 by the biochemistDr. Guenther Sawatzki, a research director of an industrialresearch department with more than 15 years of experi-ence in medical research. The company’s main activitiesare immunology, enzymology and protein biochemistry.Areas of activities are: long chain polyunsaturated fattyacids (omega 3 and 6), protein and growth, bioactive pep-tides, food allergy, enzyme technology, prebiotics andapplication of biotechnology (white) in food production.

The company’s main interest is infant nutrition. The EFSAhealth claims regulation formed the basis for planningand conducting clinical studies, especially with infants.The company’s main activities have now changed to con-sulting.

SciNuTec GmbH has been a partner for the dairy industryfor many years. Its consulting activities are limited to spe-cific areas.

Business activities



Further

Applications




SGS INSTITUT FRESENIUSGmbH

CEO: Vincent Giesue Furnari

Im Maisel 14D-65232 TaunussteinPhone +49 6128 744-0Fax +49 6128 [email protected]

SGS INSTITUT FRESENIUS is part of the SGS Group, the world’s leadinginspection, verification, testing and certification company. With our rangeof chemical, biological and physical analyses and the associated consultingservices, SGS INSTITUT FRESENIUS – as a laboratory service provider – servestraditional companies as well as innovative high-tech customers in thefields of life science, food / consumer products, agricultural and environ-mental services.

Our competence can be seen in our more than 180 certifications, accredi-tations and approvals and in our 155 years of experience in the field ofanalysis. This outstanding knowledge justifies our excellent reputation –In Germany and internationally – among manufacturers, the retail trade,service providers and end consumers.

Our work for these customers goes well beyond simply providing analyticallaboratory services. SGS INSTITUT FRESENIUS – with its analytical and advi-sory quality assurance competence – sees itself as a problem solver andadvisor in the areas of product development, manufacture and processing.

Business activities



Further

Applications




66

Siemens Healthcare DiagnosticsProducts GmbH

CEO: Stefan Wolf

Emil-von-Behring-Strasse 76D-35041 MarburgPhone +49 6421 394-201Fax +49 6421 [email protected]/diagnostics

Siemens Healthcare Diagnostics Products GmbH is theheadquarters of Siemens’ global Hemostasis, Hematol-ogy & Specialty business unit with approximately 3,000employees worldwide. As one of the largest providers inthe area of in vitro diagnostics, the company is meetingthe needs of laboratories of all sizes by offering its cus-tomers innovative products and solutions for the entirerange of patient care from a single source – from preven-tion and early detection to diagnosis, and on to treatmentand aftercare.

With its portfolio of performance-driven systems, reliablereagents and facilitating IT tools, this Siemens businessunit provides healthcare solutions for a state-of-the-artpatient management in the fields of hematology, hemo-stasis, infectious diseases, plasma proteins and drugmonitoring. All of this in conjunction with strong cus-tomer care processes. That is how the company innovatesto advance human health.

Business activities



Further

Applications




SocraTec R&D GmbH

CEO: Prof. Dr. Henning Blume

Im Setzling 35D-61440 Oberursel/TaunusPhone +49 6171 5857-10Fax +49 6171 [email protected]

We are an independent service provider for the pharma-ceutical and biotech industry with the following corecompetences:a Design and conduct of pharmacokinetic and pharma-

codynamic clinical trials, bioequivalence/biosimilar tri-als and drug-drug-interaction studies in healthy sub-jects and patient populations with special focus ononcology (phase I and II) and ophthalmology

a Clinical trials phase-III and -IV as well as non-interven-tional and post-authorisation safety studies

a Biopharmaceutical characterization of drug sub-stances and dosage forms

a Expert statements and scientific consultation as well asadvice in strategic drug development

In collaboration with affiliate companies and external part-ners, we also offer regulatory affairs services and developconcepts for novel dosage forms and their registration,e.g. preparations with optimized therapeutic properties.

Business activities



Further

Applications




67

STADApharm GmbH

CEO: Hartmut Retzlaff

Stadastrasse 2-18D-61118 Bad VilbelPhone +49 6101 603-0Fax +49 6101 [email protected] / www.stada.com

STADApharm GmbH specializes in high-quality prescrip-tion generics and is a discount agreement partner ofnumerous statutory health insurance organizations. Withthe area of diagnostics, the product portfolio alsoincludes the field of DNA-based individualized drug ther-apy. In order to support the therapies and ensure the bestpossible healthcare, a wide range of services are offeredfor doctors, pharmacists and patients.

STADApharm is a wholly owned subsidiary of STADAArzneimittel AG. In the financial year 2013, STADAArzneimittel AG achieved group sales of € 2,014.4 mil-lion, an adjusted EBITDA of € 415.2 million and adjustednet income of € 160.6 million. As of 31 December 2013,the STADA Group had 9,825 employees worldwide.

Business activities



Further

Applications




STOE & Cie GmbH

CEO: Dipl. Wirtsch.-Ing. Martin Fark

Hilpertstrasse 10D-64295 DarmstadtPhone +49 6151 988-70Fax +49 6151 [email protected]

STOE develops, manufactures and sells scientific instruments for the non-destructive analysis of substances. Based on the X-ray diffraction (XRD)method, these systems characterize single crystals and powder samplesand give answers to which substances a particular powder or crystal con-tains or at which positions atoms in solid bodies are exactly located.

STOE, originally founded in 1887, to manufacture equipment for the opti-cal analysis of crystals, has been a pioneer in powder and single crystal X-ray diffraction since the 1960’s, e.g. STOE invented and patented the trans-mission geometry technique for Powder XRD as well as, for single crystals,produced the first pixel detector XRD system with an open Eulerian cradle.

STOE is based in Darmstadt, Germany, and keeps the R&D, software pro-gramming, electrical and mechanical engineering and production all inhouse, allowing STOE to provide customers with standard as well as indi-vidual solutions. Whenever it comes to quality, STOE accepts no compro-mises. This high-level of detail is what sets STOE apart. STOE is the partnerin X-Ray Diffraction to crystallographers, chemists, material scientists andpharmacists all over the world.

Business activities



Further

Applications




68

SunChrom GmbH

CEO: Dr. Guenes Barka

Industriestrasse 27D-61381 FriedrichsdorfPhone +49 6172 953-350Fax +49 6172 [email protected]

SunChrom was founded in 1988 with the primary objec-tive to market and service products of Spark Hollandautosampler and column heaters as an exclusive distrib-utor in Germany. The company was renamed in 1993 inSunChrom GmbH which is still the sales and service forthe products of Spark Holland.

Since 1995 a complete, modular, analytical HPLC systemcan be offered by the SunChrom GmbH. A new genera-tion HPLC line will be introduced in the second half of2014.

Current Focus:a MALDI Spotter SunCollect a Micro and Analytical HPLC systems a Sample Preparation

Business activities



Further

Applications




SYHA CONSULT

CEO: Dr. Klaus Syha, MBA

Im Rosengärtchen 11D-61440 OberurselPhone +49 6171 [email protected]

a Integrated Value Chain: Business Processes – Drug Development Programs

a Competitive Advantage for Clientsa Business Processes: Strategy transformed into Programsa Preclinical Drug Development: Programs transformed into

Interventions a SYHA CONSULT supports the pharmaceutical industry in non-clinical

drug development programs of projects since 1993.a Feasibility a Business Processes: Aligning Structures and Systemsa Proof-of-Biology a Proof-of-Concept: Improving efficacy and safetya First in Human – Translational Medicinea Proof-of-Value a Preparation of Patentsa Over 15 years experience in business processes and drug development

for complex medical, neurological and psychiatric diseasesa Added Value aMolecular Strategy – Integrated Value Chaina Systems – Points of Intervention aMedicine – Complex Diseasesa Neuroscience – Functional View a Strategic R&D – R&D Strategies

Business activities



Further

Applications




69

SynapCon Ltd.

CEO: Sven Engel

POB 13 02 50D-65090 WiesbadenPhone +49 611 7039 7054Fax +49 611 7102 [email protected]

SynapCon Ltd. is offering international clinical projectmanagement and clinical monitoring combined with ITservices, consultancy and compliance services for SME´sof other branches as well. Latter includes analysis, imple-mentation and monitoring of compliance structures, qual-ity control and risk management.

We have comprehensive expertise and experience withdifferent orphan indications and pediatrics population inour clinical services.

Business activities



Further

Applications




Systec Labor-SystemtechnikGmbH

CEO: Helmut Winkelmann

Sandusweg 11D-35435 WettenbergPhone +49 6419 8211-0Fax +49 6419 [email protected]

Systec GmbH Labor-Systemtechnik was founded in 1994.It develops, manufactures and markets, laboratory auto-claves (steam sterilizers) and media preparators through-out the world. All of our managers have over twenty yearsof experience in this sector.

We develop and manufacture, certified according to ISO9001, a wide range of products for the modern labora-tory, science and research as well as biotechnology, phar-macy, quality control and production. We supply univer-sity laboratories, Max-Planck Institutes, federal and stateresearch institutions and other major research institutes,the pharmaceutical and food industries, public healthlaboratories and private laboratories as well as researchinstitutes and companies within the biotechnology, genetechnology and diagnostics sectors.

Business activities



Further

Applications




70

t2cure GmbH

CEO: Susanne Knigge

Kennedyallee 93D-60596 FrankfurtPhone +49 69 7561 468-70Fax +49 69 7561 [email protected]

t2cure is a biopharmaceutical company dedicated to thedevelopment of novel progenitor cell-based regenera-tive therapeutics to provide new treatment options topatients suffering from cardiac or peripheral vascular dis-eases.

t2cure is active in two therapeutic areas: cardiac diseaseswith focus on myocardial infarction and chronic heart dis-ease; and peripheral arterial diseases with focus onthromboangiitis obliterans. More than 800 patients weretreated with the progenitor cell-based therapy to date.The therapy is available to patients in Germany at special-ized clinical centers.

Business activities



Further

Applications




Targos Molecular PathologyGmbH

CEO: Dr. Thomas Henkel

Germaniastrasse 7D-34119 KasselPhone +49 561 50045-0Fax +49 561 [email protected]

Targos has established itself as premier partner of theinternational pharmaceutical and diagnostic industry forthe clinical validation and approval of novel targetedtherapies and companion diagnostics.

The services include clinical biomarker research anddevelopment as well as training and consulting for inter-national healthcare professionals. With a large interna-tional network and strategic partners in China and the US,Targos is able to offer its services worldwide.

Business activities



Further

Applications




71

TAVARGENIX GmbH

CEO: Dipl.-Biol., Dipl.-Kfm. Stefan M. Sauter

Reißstrasse 1aD-64319 PfungstadtPhone +49 6151 95055-50Fax +49 6151 [email protected]

Aim of TAVARGENIX is the research, development andmarketing of drugs against all types of aggressive andinvasive human cancers. We have already found apromissing anti-cancer compound against our patentedTKTL1 drug target which is the core element of theenergy methabolism of all aggressive and invasive can-cers. Currently, we are doing pre-clinical tests of thisalready patented anti-TKTL1 compound. When you areinterested in what we do, please do not hesitate to con-tact us.

Business activities



Further

Applications




TAVARLIN AG

CEO: Ralf Schierl

Reißstrasse 1aD-64319 PfungstadtPhone +49 6151 95055-50Fax +49 6151 [email protected]

TAVARLIN AG develops and sells innovative blood testsfor the detection of tumor diseases. In 2007, Dr. JohannesCoy and Ralf Schierl founded the company to improvediagnosis opportunities and therapy options for cancerdiseases. On the basis of Dr. Coy experiences (having dis-covered the gens TKTL1 and DNaseX/Apo10 in 1995 atthe DKFZ), the company developed the EDIM blood test.With this immunological diagnostic procedure, tumorscan be detected and characterized much earlier, eventhose for which up till now, only inaccurate tests wereavailable. Tumor and biomarkers TKTL1 and DNaseX/Apo10 are responsible for fundamental biophysicalmechanisms in mammalian cells. These mechanisms alsoplay a key role in tumor cells, it prevents the death andenable invasive growth and the formation of metastases.EDIM-Apo10/TKTL-1 bllod tests are exclusively offered bybiovis Laboratory in Limburg which is part of the SonicGroup.

Business activities



Further

Applications




72

tec-lab GmbH

CEO: Sven Benedikt

Idsteiner Strasse 78D-65232 TaunussteinPhone +49 6126 50949-50Fax +49 6126 [email protected]

CRYOTECHNOLOGY – EXPERIENCE SINCE 1993

For over 20 years, we have been advising our customersand implementing complex solutions. We have installedcountless cryogenic systems in this period, whether as acomplete or partial solution. Our technical know-how hascontributed to our good reputation. We avoid problemsbefore they even occur.

We are the direct distributor of Taylor-Wharton.

Business activities



Further

Applications




TIGO GmbH

CEO: Dr. med. Hans-Günther Grigoleit

Joh.-Seb.-Bach-Strasse 27D-65193 WiesbadenPhone +49 611 520 509Fax +49 611 599 [email protected]

TIGO GmbH is a biotech startup company with a uniqueand patented technology platform in the field of recom-binant receptor antagonists and other modulators to thecytokine interferon gamma and other modulators tointerferon gamma, e.g. interferon beta.

TIGO’s unique approach is to develop such antagonistsand modulators to counteract the negative effects ofinterferon gamma in diseases such as alopecia areata(patchy hair loss) and transplant vasculopathy.

Business activities



Further

Applications




73

Trifolio-M GmbH

CEO: Dr. Hubertus Kleeberg

Dr.-Hans-Wilhelmi-Weg 1D-35633 LahnauPhone +49 6441 20977-0Fax +49 6441 [email protected]

Since 1985, Trifolio-M GmbH has been committed in theR&D of highly pure biomaterials. Located in the center of Hessen in Lahnau, the company has a worldwide net-work of marketing partners and supplies plant protectionproducts, biocides, health promotion products andpheromones.

Especially neem extracts play a decisive role, for examplein NeemAzal-T/S, a leading product for ecological plantprotection.

Business activities



Further

Applications




Trinova Biochem GmbH

CEO: Arthur Ronzheimer

Rathenaustrasse 2D-35394 GießenPhone +49 641 94390-0Fax +49 641 [email protected]

Trinova Biochem offers products for genetic toxicology(S9 products, AMES Test, Umu Test), assays for in vitrostem cell testing and cytogenetic cell culture media.

Business activities



Further

Applications




74

Veyx-Pharma GmbH

CEO: Armin Hess

Soehreweg 6D-34639 SchwarzenbornPhone +49 5686 99860Fax +49 5686 [email protected]

Veyx-Pharma GmbH is a medium-sized animal healthcompany. Its activities center round prophylactic treat-ment and maintaining the performance of farm animals.

The company’s product range is focused on reproductioncontrol and birth-influencing preparations for farm ani-mals and pets, proteolytic enzymes and microemulsionsof vital nutrients as a physiological support to meet thewide-ranging needs of farm animals and pets.

Business activities



Further

Applications




VIRO-IMMUN Labor Diagnostika GmbH

CEO: Dr. Massoud Hodawand

In der Au 29D-61440 OberurselPhone +49 6171 628-100Fax +49 6171 [email protected]

VIRO-IMMUN Labor-Diagnostika GmbH specializes ininfectious and autoimmune diseases. Its product rangecovers the most common parameters for diagnosing suchdiseases and it is one of the leading German producersof ELISAs, IFAs and Immunoblots. The complete productrange is fully CE – marked, QM-System certified by TÜVSüd, Germany. VIRO-IMMUN offer maximum flexibility oftests kits (size, contents, number / volume of reagents,BULK) in accordance to customer’s equipment andprocess requirements: maximum customer orientation,sample throughput and system efficiency. VIRO-IMMUNhas established a growing network of local distributorsaround the world.

Business activities



Further

Applications




75

VIROSCREEN & VIROFEM diagnostics GmbH

CEO: Erwin Buchner

Borsigstrasse 7aD-65205 WiesbadenPhone +49 6122 5889-733Fax +49 6122 [email protected]

VIROSCREEN & VIROFEM diagnostics GmbH is the pro-ducer and owner of the only test with a prognostic markerfor cervical cancer, VIRO-safe.

Business activities



Further

Applications




Weiss Klimatechnik GmbH

CEOs: Peter R. Manolopoulos, Edwin Zijlstra

Greizer Straße 41-49D-35447 Reiskirchen-LindenstruthPhone +49 6408 846-500Fax +49 6408 [email protected]

Weiss Klimatechnik specializes in innovative, high-qualityventilation technology. Its air-conditioning systems areused wherever an optimal climate is required for produc-tion processes. The company provides clean room sys-tems for all classes of clean room, for example for thepharmaceutical, microelectronics, biotechnology, geneticengineering, medical and laboratory sectors.

Business activities



Further

Applications




76

ZEDIRA GmbH

CEOs: Dr. Ralf Pasternack, Dr. Martin Hils

Roesslerstrasse 83D-64293 DarmstadtPhone +49 6151 325-100Fax +49 6151 [email protected]

Zedira is a clinical stage biopharmaceutical company. Itspecializes in bio-medical problems involving the trans-glutaminase enzyme family. Transglutaminases are coreelements in various human diseases, for example celiacdisease (gluten intolerance). Zedira produces and mar-kets special reagents for research and development anddiagnostic products. In addition, it is engaged in drug dis-covery. This includes research into small molecules thatselectively block dysregulated transglutaminases.

Zedira’s second area of indication is the prevention ofthrombosis (anticoagulation). Inhibiting blood plasmatransglutaminase (factor XIII) enables selective interven-tion in the coagulation process. The company receivesfinancial support from the German Ministry for Educationand Research for its research work on therapies.

Business activities



Further

Applications




Classified Register

77

Wav

ebre

akm

edia

Mic

ro |

Fo

tolia

.co

m

78

Classified Register

A Seite 15

AB Enzymes GmbH • • • • • • • • AbbVie GmbH & Co. KG • • • • • • •ABT Armbruster Biotechnologie GmbH • • • •Accovion GmbH • • •AdiuTide Pharmaceuticals GmbH • • •Advanced Cyclotron Systems GmbH • • • • • • • •Aeterna Zentaris GmbH • • •Alcedis GmbH • • •AlphaScience GmbH • • • • Analyticon Biotechnologies AG • • • • • • • • anamed Elektrophorese GmbH • • • • • • • AXIOM GmbH • • • • • • •

B Seite 21

BAG Health Care GmbH • • • • • • •BCNP Consultants GmbH • • • • • • • •Biaffin GmbH & Co KG • • • • • •Biebertaler Blutegelzucht GmbH • • • • • •bio.logis GmbH • • • •bioactiva diagnostica GmbH • • • • • biomedis Laborservice GmbH • • • • • • • •BioSciTec GmbH • • • • • • • •BioSpring GmbH • • • • • • •Biotec-Fischer GmbH • • • • BIT Analytical Instruments GmbH • • • • • •Bochem Instrumente GmbH • • • • • • • • •BRAIN AG • • • • • • • • • •

Rese

arch

Dev

elo

pm

ent

Pro

duc

tion

Mar

ketin

g

Sale

s

Serv

ices

Furt

her

Ag

ricu

lture

Che

mis

try

Dia

gno

stic

s

Eng

inee

ring

Envi

ronm

enta

l Pro

duc

tion

Foo

d/F

eed

Med

icin

e/P

harm

aceu

tical

s

Bussiness Activities Applications

79

Classified Register

C Seite 27

Capricorn Scientific GmbH • • • •Cepheid GmbH • • • • • • Chemgineering Technology GmbH • • • • • •Chugai Pharma Germany Ltd. • • • • •CIRI GmbH • • •CSL Behring GmbH • • • •Cyntegrity Germany GmbH • • •CytoTools AG • • • • • •

D Seite 31

Danico GmbH • • • • • • • • • • •Dentons LLP • • •Diagnostics Biochem Deutschland GmbH • • • • • • DRG Diagnostics GmbH • • • •

E Seite 33

eBioscience GmbH – an Affymetrix company • • • • • •ELEMENTAR Analysensysteme GmbH • • • • • • • • •Engelhard Arzneimittel GmbH & Co. KG • • • • • • Ergomed Group GmbH • • • •Bernd Euler Biotechnologie – Mikrobiologie • • • • • • • • •Evonik Industries AG • • • • • • • •

Rese

arch

Dev

elo

pm

ent

Pro

duc

tion

Mar

ketin

g

Sale

s

Serv

ices

Furt

her

Ag

ricu

lture

Che

mis

try

Dia

gno

stic

s

Eng

inee

ring

Envi

ronm

enta

l Pro

duc

tion

Foo

d/F

eed

Med

icin

e/P

harm

aceu

tical

s


80

Classified Register

F Seite 36

Fiebig – Nährstofftechnik • • • •FluidX Germany • • • • • • •Fresenius Kabi AG • • •Fuchs Patentanwälte Partnerschaft mbB • • • • • • • •

G Seite 38

GBG Forschungs GmbH • •Genius GmbH • • • • • • •GenXPro GmbH • • • • • • •Genzyme GmbH – a Sanofi company • • •GFE Blut GmbH • • • • • • • Patentanwälte Gierlich& Pischitzis Partnerschaftsgesellschaft • • • • • • • •GOBIO GmbH • • • • • •

H Seite 42

Hilgenberg GmbH • • • • • • • • •humatrix AG • • • •Hycor Europe Bio Crest B.V. • • •

I Seite 43

IBACON GmbH • • • • • •ID-Labor GmbH • • • Immundiagnostik AG • • • • • •Immunolab GmbH • • • • • • • • •INTEGRA Biosciences GmbH • • • • • • • • •Intermed GmbH • • • •

Rese

arch

Dev

elo

pm

ent

Pro

duc

tion

Mar

ketin

g

Sale

s

Serv

ices

Furt

her

Ag

ricu

lture

Che

mis

try

Dia

gno

stic

s

Eng

inee

ring

Envi

ronm

enta

l Pro

duc

tion

Foo

d/F

eed

Med

icin

e/P

harm

aceu

tical

s


81

Classified Register

J Seite 46

JUMO GmbH & Co. KG • • • • • • • • •

K Seite 47

Keller Medical GmbH • • • • KEPOS GmbH • Otto E. Kobe KG • • • • • • • • •

L Seite 48

LI-COR Biosciences GmbH • • • • • • • •LOT-QuantumDesign GmbH • • • •

M Seite 49

Matrix BioScience GmbH • • • • • • •MedSurv GmbH • • •Merck KGaA • • • • • • • • • •Mettler-Toledo GmbH • • • • • • • •Milenia Biotec GmbH • • • • • • • •MK Versuchsanlagen GmbH • • • • • •MORPHISTO GmbH • • • • • • • •MOTUS Engineering GmbH & Co. KG • • • • • • • • •mti diagnostics GmbH • • • • • • Mundipharma GmbH • • • • • • •

Rese

arch

Dev

elo

pm

ent

Pro

duc

tion

Mar

ketin

g

Sale

s

Serv

ices

Furt

her

Ag

ricu

lture

Che

mis

try

Dia

gno

stic

s

Eng

inee

ring

Envi

ronm

enta

l Pro

duc

tion

Foo

d/F

eed

Med

icin

e/P

harm

aceu

tical

s


82

Classified Register

N Seite 54

N-Zyme BioTec GmbH • • • • • • •nadicom GmbH • • • • • • •NeuroCode AG • • • •New England Biolabs GmbH • • • • • • • • • • • •

O Seite 56

onoff engineering GmbH • • • • • • • • •

P Seite 57

PAREXEL International GmbH • • •PKCie GbR • • • • • •Polygen GmbH • • • • • PPH plus GmbH & Co. KG • •Premier Research Germany Ltd. • •Preventis GmbH • • • • • Prolytic GmbH • • • • • • •Provadis School of International Management&TechnologyAG (•) (•) • •PURIMEX • • • • •

Q Seite 61

Quintiles GmbH • •

Rese

arch

Dev

elo

pm

ent

Pro

duc

tion

Mar

ketin

g

Sale

s

Serv

ices

Furt

her

Ag

ricu

lture

Che

mis

try

Dia

gno

stic

s

Eng

inee

ring

Envi

ronm

enta

l Pro

duc

tion

Foo

d/F

eed

Med

icin

e/P

harm

aceu

tical

s


83

Classified Register

R Seite 62

R-Biopharm AG • • • • • • • RD-RatioDiagnostics GmbH • • • • • DR. RIETHMÜLLER M/R/S GmbH • • • • • •RSC Pharma LTD. & Co. KG • • • • • • •

S Seite 64

Sanofi-Aventis Deutschland GmbH • • • • • • • •ScheBo Biotech AG • • • • • • • SciNuTec GmbH • • • • • • • SGS INSTITUT FRESENIUS GmbH • • • • • •Siemens Healthcare Diagnostics Products GmbH • • • • • • • SocraTec R&D GmbH • • • •STADApharm GmbH • • • • • • • •STOE & Cie GmbH • • • SunChrom GmbH • • • • • • • • SYHA CONSULT • • • • • • •SynapCon Ltd. • •Systec Labor-Systemtechnik GmbH • • • • • •

Rese

arch

Dev

elo

pm

ent

Pro

duc

tion

Mar

ketin

g

Sale

s

Serv

ices

Furt

her

Ag

ricu

lture

Che

mis

try

Dia

gno

stic

s

Eng

inee

ring

Envi

ronm

enta

l Pro

duc

tion

Foo

d/F

eed

Med

icin

e/P

harm

aceu

tical

s


84

Classified Register

T Seite 70

t2cure GmbH • • •Targos Molecular Pathology GmbH • • • • •TAVARGENIX GmbH • • • • •TAVARLIN AG • • • • • tec-lab GmbH • • • • • • • •TIGO GmbH • • • • •Trifolio-M GmbH • • • • • • • • •Trinova Biochem GmbH • • • • •

V Seite 74

Veyx-Pharma GmbH • • • • • • • •VIRO-IMMUN Labor Diagnostika GmbH • • • • • VIROSCREEN & VIROFEM diagnostics GmbH • • • • • • •

W Seite 75

Weiss Klimatechnik GmbH • • • • • • • • • • •

Z Seite 76

ZEDIRA GmbH • • • • • • •

Rese

arch

Dev

elo

pm

ent

Pro

duc

tion

Mar

ketin

g

Sale

s

Serv

ices

Furt

her

Ag

ricu

lture

Che

mis

try

Dia

gno

stic

s

Eng

inee

ring

Envi

ronm

enta

l Pro

duc

tion

Foo

d/F

eed

Med

icin

e/P

harm

aceu

tical

s


85

Lise

Gag

ne |

ist

ock

ph

oto

.co

m

R &D Centers

86

R & D Centers

Industrial Parks & Technology Centers

Behringwerke MarburgPharmaserv GmbH & Co. KG

Emil-von-Behring-Strasse 87D-35041 Marburg

Bernd SchönebergPhone +49 6421 3034-780Fax +49 6421 [email protected], www.pharmaserv.de

Biotech-Park Pfungstadt Verwaltungs-GmbHAn der neuen Bergstrasse 17D-64319 Pfungstadt

[email protected]://biotech-park-pfungstadt.de

Campus Oberhafen BEOS AGHanauer Landstrasse 340D-60314 Frankfurt am Main

Janina KayaPhone +49 69 6560655-22Fax +49 69 [email protected], www.beos.net

Fechenheim Industrial ParkAlt-Fechenheim 34D-60386 Frankfurt am Main

Rafael ReiserPhone +49 69 4109-2270Fax +49 69 [email protected]

FIZ Frankfurt Biotechnology Innovation Center GmbH

Altenhöferallee 3D-60438 Frankfurt am Main

Dr. Christian GarbePhone +49 69 800865-0Fax +49 69 [email protected]

Griesheim Industrial ParkInfrasite Griesheim GmbH

Stroofstrasse 27D-65933 Frankfurt am Main

Dr. Andreas BrockmeyerPhone +49 69 3800-2100Fax +49 69 3800-2022andreas.brockmeyer@infrasite-griesheim.comwww.infrasite-griesheim.com

Industrial Park HöchstInfraserv GmbH & Co. KG

Industriepark Höchst D 706D-65926 Frankfurt am Main

Dr. Lothar MeierPhone +49 69 305-20300Fax +49 69 [email protected]

Kalle Albert Industrial ParkInfraServ GmbH & Co. KG

Kasteler Strasse 45D-65203 Wiesbaden

Michael BehlingPhone +49 611 962-6770Fax +49 611 [email protected]

NTZ Naturwissenschaftliches Technologiezentrum Marburg

Stadtwerke Marburg Immobilien-GmbHSoftwarecenter 3D-35037 Marburg

Tomas SchneiderPhone +49 6421 205-160Fax +49 6421 [email protected]

TIG Technologie- und Innovationszentrum Gießen GmbH

Winchesterstrasse 2D-35394 Gießen

Antje BienertPhone +49 641 948226-0Fax +49 641 [email protected] www.tig-gmbh.de

Wolfgang Industrial Park Evonik Industries AGRodenbacher Chaussee 4D-63457 Hanau

Phone +49 6181 59-01www.industriepark-wolfgang.de

87

R & D Centers

Research Centers

DECHEMA ForschungsinstitutTheodor-Heuss-Allee 25D-60486 Frankfurt am Main

Prof. Dr. Jens SchraderPhone +49 69 7564-422Fax +49 69 [email protected]

Fraunhofer Institute for Molecular Biology and Applied Ecology IME e.V.

Projektgruppe Translationale Medizin & Pharmakologie (TMP)Theodor-Stern-Kai 7D-60596 Frankfurt am Main

Dr. Torsten ArndtPhone +49 69 6301-87159Fax +49 69 [email protected]/de/geschaeftsfelder/TMP.html

Georg-Speyer-HausInstitute for Tumor Biology and Experimental Therapy

Paul-Ehrlich-Strasse 42-44D-60596 Frankfurt am Main

Prof. Dr. Florian GretenPhone +49 69 63395-232Fax +49 69 [email protected]

KSRM Klinisches Studienzentrum Rhein-MainTeil der Fraunhofer IME e.V.

Projektgruppe Translationale Medizin & Pharmakologie (TMP)Schleusenweg 22D-60528 Frankfurt am Main

Dr. Frank BehrensPhone +49 69 6301-7302Fax +49 69 [email protected]/de/geschaeftsfelder/TMP/Leistungsangebot_Klinische_Forschung.html

Max Planck Institute for Brain ResearchMax-von-Laue-Strasse 4D-60438 Frankfurt am Main

Dr. Arjan VinkPhone +49 69 850033-2900Fax +49 69 [email protected]

Max Planck Institute for Heart and Lung ResearchW.G. Kerckhoff-Institute

Ludwigstrasse 43D-61231 Bad Nauheim

Prof. Dr. Stefan OffermannsPhone +49 6032 7051-201Fax +49 6032 [email protected]

Max Planck Institute for Terrestrial MicrobiologyKarl-von-Frisch-Strasse 10D-35043 Marburg

Prof. Dr. Ralf ConradPhone +49 6421 178-801Fax +49 6421 [email protected]

Max-Planck-Institute of BiophysicsMax-von-Laue-Strasse 3D-60438 Frankfurt am Main

Prof. Dr. Dr. Hartmut MichelPhone +49 69 6303-1001Fax +49 69 [email protected]

Paul-Ehrlich-InstitutBundesinstitut für Impfstoffe und biomedizinische Arzneimittel

Paul-Ehrlich-Strasse 51-59D-63225 Langen

Prof. Dr. Klaus CichutekPhone +49 6103 77-0Fax +49 6103 [email protected]

88

R & D Centers

Universities: Technology & Transfer

Frankfurt University of Applied SciencesResearch, Further Education and Transfer

Nibelungenplatz 1D-60318 Frankfurt am Main

Kristiane Seidel SperfeldPhone +49 691 5332-162Fax +49 691 [email protected]

Johann Wolfgang von Goethe-University FrankfurtWissens- und Technologietransfer

Grüneburgplatz 1D-60323 Frankfurt am Main

Dr. Cornelius GröschelPhone +49 69 798-13636Fax +49 69 [email protected]

Hochschule Fresenius gGmbHFachbereich Chemie&Biologie

Limburger Straße 2D-65510 Idstein

Institute for analytical research (IFAR)Prof. Dr. Thomas KnepperPhone +49 6126 [email protected]

Institute for Biomolecular Research (IBR)Prof. Dr. Klaus SchreiberPhone +49 6126 9352 [email protected]

www.hs-fresenius.de

Hochschule Geisenheim UniversityAbteilung Wissenstransfer

Von-Lade-Straße 1D-65366 Geisenheim

Prof. Dr. Manfred GroßmannPhone +49 6722 502-331Fax +49 6722 [email protected]

University of Applied Sciences DarmstadtService-Zentrum Forschung und Transfer

Haardtring 100D-64295 Darmstadt

Jürgen LinneweberPhone +49 6151 16-8015Fax +49 6151 [email protected]

University of Applied Sciences FuldaAbteilung Forschung und Transfer

Marquardstrasse 35D-36039 Fulda

Christina LangsdorfPhone +49 661 9640-157Fax +49 661 [email protected]

Offenbach University of Art and DesignBüro für Wissenstransfer

Schlossstrasse 31D-63065 Offenbach am Main

Ulrike GrünewaldPhone +49 69 80059-166Fax +49 69 [email protected]

RheinMain University of Applied SciencesResearch /Transfer / Interaction

Kurt-Schumacher-Ring 18D-65197 Wiesbaden

Michael AntonPhone +49 611 9495-1123Fax +49 611 [email protected]

Justus-Liebig-University GießenWissens- und Technologietranfer

Bismarckstrasse 24D-35390 Gießen

Dr. Ulrich DölpPhone +49 641 99-12140Fax +49 641 [email protected]

Philipps-University MarburgAbteilung für Forschung und Wissenstransfer

Biegenstrasse 10D-35032 Marburg

Sandra BasenauPhone +49 6421 28-26938Fax +49 6421 28-27021sandra.basenau@verwaltung.uni-marburg.dewww.uni-marburg.de/forschung

89

R & D Centers

Technische Hochschule MittelhessenAbteilung Forschung und Transfer

Wiesenstrasse 14D-35390 Gießen

Bärbel GriebPhone +49 641 309-1349Fax +49 641 [email protected]/forschung

Technische Universität DarmstadtDezernat Forschung / Referat Kooperationen

Karolinenplatz 5D-64289 Darmstadt

Dr. Ing. Nicolas ReppPhone +49 6151 572-06Fax +49 6151 [email protected]

Universität Kassel UniKasselTransfer

Mönchebergstrasse 7D-34109 Kassel

Dr. Oliver FrommPhone +49 561 804-2734Fax +49 561 [email protected]

Technology Transfer

Enterprise Europe Network (EEN) HessenHessen Trade & Invest-GmbH

Konradinerallee 9D-65189 Wiesbaden

Dr. Khaled SnouberPhone +49 611 95017-8998Fax +49 611 [email protected]

GINo Gesellschaft für Innovation NordhessenMönchebergstrasse 7D-34125 Kassel

Dr. Heike KrömkerPhone +49 561 804-1984Fax +49 561 [email protected]

Innovectis GmbH Gesellschaft für Innovations-Dienstleistungen

Altenhöferallee 3D-60438 Frankfurt am Main

Dr. Otmar SchöllerPhone +49 69 2561632-0Fax +49 69 [email protected]

TransMIT GmbHGesellschaft für Technologietransfer

Kerkrader Strasse 335394 Gießen

Dr. Peter StumpfPhone +49 641 94364-0Fax +49 641 [email protected]

90

R & D Centers

Clusters & Networks

Technologielinie Hessen-BiotechHessen Trade & Invest GmbH

Konradinerallee 9D-65189 Wiesbaden

Dr. Detlef TerzenbachHead of Bio / Nano / EnvironmentPhone +49 611 95017-8613Fax +49 611 [email protected] www.hessen-biotech.de

Hessen-Biotech coordinates the activities of the Hessian Ministry of Economics in the funding ofbiotechnology enterprises. It is a platform for information, communication and cooperation inbiotechnology.

Cluster for Individualized ImmuneIntervention(Ci3) UG

Kupferbergterrasse 17-19D-55116 Mainz

Dr. Andrea SchilzPhone +49 6131 62305-81Fax +49 6131 [email protected]

Ci3 bundles the outstanding expertise in the Rhine-Main cluster region in the area of biotechnologybased on individualized medicine focusing on immune therapies and diagnostics.

DECHEMA Gesellschaft für Chemische Technik und Biotechnologie e.V.

Theodor-Heuss-Allee 25D-60486 Frankfurt am Main

Dr. Kathrin RübberdtPhone +49 69 7564-277Fax +49 69 [email protected]

As a scientific-technological non-profit organization,DECHEMA represents the German chemical engineering and biotechnology in the areas of science, economy, politics and society.

House of Pharma & Healthcare e.V.Theodor-W.-Adorno-Platz 1D-60323 Frankfurt am Main

Dr. Otto Quintus RussePhone +49 69 6301 84900Fax +49 69 6301 [email protected]

The House of Pharma & Healthcare is an association ofall parties involved in the pharmaceutical value chain.It brings together stakeholders from universities, non-university research institutions, pharmaceutical industry, SMEs, political parties, health insurance com-panies, patient organizations, physicians, pharmacists,health initiatives and regulatory authorities with theaim of achieving significant synergies.

Rhine-Main Chemical & Pharmaceutical ClusterProvadis School of International Management and Technology AG

Industriepark Höchst, Gebäude B 845D-65926 Frankfurt am Main

Prof. Dr. Udo Müller-NehlenPhone +49 69 305-5087Fax +49 69 305-16277Udo.Mueller-Nehler@provadis-hochschule.dewww.rhein-main-cluster.de

Höchst Industrial Park and the Rhine-Main region haveinitiated a cluster of chemical and pharmaceuticalcompanies, which are embedded in a network that has evolved over the years.

Science4Life e.V.Industriepark Höchst, Gebäude H831D-65926 Frankfurt am Main

Christiane WohlersPhone +49 69 305-25922Fax +49 69 [email protected]

Science4Life is an initiative to support founders in thefield of Life Sciences and Chemistry. This initiative issupported by the State of Hessen and by the globalhealthcare leader Sanofi.

91

R & D Centers

timmTechnologie & Innovation Medizinregion Mittelhessen

c/o TransMIT GmbHKerkrader Strasse 3D-35394 GießenPhone +49 641 94364-0Fax +49 641 [email protected]

timm provides support in the cooperation betweenmedical research institutions and industry and con-tributes to R&D in the fields of medical technology,pharmaceuticals and health care in central Hessen

ZAFES the Center for Drug Research, Development and Safety

Theodor-Stern-Kai 7D-60590 Frankfurt am Main

Dr. Torsten ArndtPhone +49 69 6301-87159Fax +49 69 [email protected]

The aim of ZAFES, the Center for Drug Research, Development and Safety, is to combine the best elements of the three worlds “University”, “Pharma-ceutical Industry” and “Biotechnology” to come to innovative medical solutions much faster.

Publication series of Hessen-Biotech

Volume 1 FörderoptionenFür technologieorientierte Unternehmenin Hessen

Volume 2 Werkzeuge der NaturWeiße Biotechnologie in Hessen

Volume 3 Hessen – Gateway to Biomanufacturingin EuropeA practical Guide to Sites and Servicesfor GMP-Production

Volume 4 Hessen – Your Gateway to the Diagnostics Market in EuropeA practical Guide to Services and Technology fort he Diagnostic Industry

Volume 5 Medizintechnik in Hessen – Strukturen und PotenzialeErgebnisse einer Unternehmens-befragung

Volume 6 Competence Atlas Hessen-BiotechThe Spectrum of Biotechnology Companies in Hessen 2012

Volume 7 Hessen – das Tor zum europäischenDiagnostikmarktWegweiser für Dienstleistungen und Technologien in der hessischen In-vitro-Diagnostik-Industrie

Volume 8 Hessen – Gateway to ContractResearch in EuropeA practical Guide to Sites and Services,second edition

Volume 9 Biotech in HessenDaten und Fakten / Facts and Figures

Volume 10 Chemical Parks in HessenProfessional Sites and Services forPharma, Biotech and Chemistry in Central Europe

Industrieparks in HessenInnovative Standorte für die Bio-,Pharma- und Chemieindustrie

Volume 11 Industrielle Biotechnologie in HessenEin Streifzug durch die Anwender-branchen

Industrial Biotechnology in HessenA Guided Tour through the User Sector

Volume 12 Raum für InnovationBiotechnologiestandort Hessen

Room for Innovations HessenLocation for Biotechnology

Volume 13 Personalisierte Medizin in HessenNeue Technologien für maßgeschneiderte Therapien

Volume 14 Medizintechnik in HessenErgebnisse einer Standortanalyse undUnternehmensbefragung

Medical Technology in HessenResults of a Location Study and Company Survey

Volume 15 Diagnostik-Industrie in Hessen

Diagnostics Industry in Hessen

Volume 16 Nanotechnologie und MedizinEine Schlüsseltechnologie kommt an

Volume 17 Competence Atlas Hessen-BiotechThe Spectrum of Biotechnology Companies in Hessen 2015

Information / Download:www.hessen-biotech.de/publikationen


www.htai.de

EUROPEAN UNIONInvesting in your future –European RegionalDevelopment Fund

Documents

Competence Atlas Hessen-Biotech€¦ · Competence Atlas Hessen-Biotech The Spectrum of Biotechnology Companies in Hessen 2015 Volume 17 of the publication series of Hessen-Biotech